

CURRICULUM VITAE

Date prepared: 02/01/2010

Name: Steven Peter Treon
Birthplace: Greensboro, N.C., U.S.A.
Office Address: Dana Farber Cancer Institute
44 Binney Street, M548, Boston, MA 02115 USA
Website: <http://www.stevenptreon.com>
E-mail: steven_treon@dfci.harvard.edu

Education:

1985 B.A. Boston University, Boston, MA.
1987 M.A. Boston University.
1991 Ph.D. Boston University (*Cancer Immunology*).
1993 M.D. Boston University School of Medicine.

Postdoctoral Training:

1991-1992 Postdoctoral Fellow, Department of Microbiology, Boston University School of Medicine, Boston, MA.
1992-1993 Intern in Medicine, Boston University Medical Center, Boston, MA.
1993-1994 Junior Assistant Resident, Internal Medicine, Boston University Medical Center, Boston MA.
1994-1995 Senior Assistant Resident, Internal Medicine, Boston University Medical Center, Boston MA.
1995-1998 Clinical and Research Fellow in Hematology and Oncology, Massachusetts General Hospital and Dana Farber Cancer Institute, Boston, MA
1995-1998 Research Fellow in Medicine, Harvard Medical School, Boston MA.

Licensure and Certification:

1993 Massachusetts Medical Licensure
1995 American Board of Internal Medicine Certificate
1997 American Board of Internal Medicine, Medical Oncology Certificate

Academic Appointments:

1993-1999	Instructor in Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA.
1993-1999	Instructor in Microbiology, Boston University School of Medicine, Boston, MA.
1998-2005	Instructor in Medicine, Harvard Medical School, Boston, MA.
2005-2009	Assistant Professor in Medicine, Harvard Medical School, Boston, MA
2009-	Associate Professor in Medicine, Harvard Medical School, Boston, MA

Hospital or Affiliated Institution Appointments:

1998-	Associate Physician, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
2000-	Clinician and Researcher, Department of Medical Oncology, Dana Farber Cancer Institute.

Major Administrative Responsibilities:

1998-2000	Medical Director, Harvard Internal Medicine Associates, PC.
2000-2005	Director, Waldenstrom's Macroglobulinemia Program, Dana Farber Cancer Institute.
2005-	Director, Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute.

Major Committee Assignments:**Hospital or Affiliated Institution:**

1997-1998	Fellowship Program Committee, Member, Dana Farber/Partners Hematology/Oncology, Boston, MA.
-----------	---

National:

1999-2004	Advisory Board, Member, Genentech, Inc., San Francisco, CA.
1999-2004	Advisory Board, Member, IDEC Pharmaceuticals, Inc., San Diego CA.
2000	Waldenstrom's Macroglobulinemia Advisory Committee, Member, National Institutes of Health, Bethesda MD.
2000	Rituxan Investigators Annual Meeting, Co-Chair, Washington DC.
2004	Educational Session, Faculty and Session Chair, American Society for Hematology Annual Meeting, San Diego CA.
2004	B-cell Summit, Planning Committee and Session Moderator, San Diego CA.
2004	Rituximab Investigators Annual Meeting, Co-Chair, Miami FL.

- 2004- Waldenstrom's Macroglobulinemia Clinical Trials Group, Chair, Boston MA.
- 2005 Abstract Reviewer, American Society of Hematology.
- 2005 Multiple Myeloma-Genetics and Cytogenetics, Session Chair, American Society of Hematology, Atlanta GA.
- 2006-2007 Scientific Program Committee, Member, American Society of Clinical Oncology.
- 2007 Multiple Myeloma-Therapy, Chair, American Society of Clinical Oncology, 2007.

International:

- 2000- Scientific Advisory Board, Member, International Waldenstrom's Macroglobulinemia Foundation, Sarasota FL.
- 2000-2001 Scientific Advisory Board, Chair, Research Fund for Waldenstrom's, New York, NY.
- 2000-2001 Program Committee, Member, VIIIth International Workshop on Multiple Myeloma, Banff, Canada.
- 2000-2001 1st International Scientific Symposium for Waldenstrom's Macroglobulinemia, Chair, Banff, Canada.
- 2001 1st International Patient and Physician Summit on Waldenstrom's Macroglobulinemia, Chair, Boston MA.
- 2001 Program Committee, Member, Monoclonal Antibody Congress, Banff, Canada.
- 2002 2nd International Workshop on Waldenstrom's Macroglobulinemia, Co-Chair, Athens, Greece.
- 2002 Consensus Panels on Management and Therapy of Waldenstrom's Macroglobulinemia, Chair, Athens, Greece.
- 2003 Scientific Advisory Board, Member, IXth International Workshop on Multiple Myeloma, Salamanca, Spain.
- 2003 2nd International Scientific Symposium for Waldenstrom's Macroglobulinemia, Session Chair, Salamanca, Spain.
- 2003 2nd International Patient and Physician Summit on Waldenstrom's Macroglobulinemia, Co-Chair, Los Angeles, CA.
- 2003 Planning Committee, Member and Workshop Chair, Monoclonal Antibody Congress, Banff, Canada.
- 2004 3rd International Workshop on Waldenstrom's Macroglobulinemia, Co-Chair, Paris, France.
- 2005 Multiple Myeloma Session, Chair, 9th International Workshop on Malignant Lymphoma, Lugano, Switzerland.
- 2005 Symposium on Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia, Chair, 9th International Workshop on Malignant Lymphoma, Lugano, Switzerland.
- 2006-2007 Organizing Committee, Member, 10th International Workshop on Multiple Myeloma, Kos, Greece.

- 2007 Symposium on Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia, Chair, 4th International Workshop on WM, Kos, Greece.
- 2007 Consensus Panel on Therapy of Waldenstrom's Macroglobulinemia, Co-Chair, 4th International Workshop on WM, Kos, Greece.
- 2008 5th International Workshop on Waldenstrom's Macroglobulinemia, Co-Chair, Stockholm, Sweden.
- 2008 Consensus Panel on Therapy of Waldenstrom's Macroglobulinemia, Co-Chair, 5th International Workshop on WM, Stockholm, Sweden.
- 2009 Session Chair, Novel Therapeutics in Multiple Myeloma, 12th International Workshop on Multiple Myeloma, Washington D.C., USA.
- 2009 3rd International Patient and Physician Summit on Waldenstrom's Macroglobulinemia, Summit Chair, Boston, USA.

Professional Societies:

- 1991- American Medical Association, Member.
- 1998- American Society of Hematology, Member.
- 1998- American Society for Clinical Oncology, Member.
- 1999 Massachusetts Medical Society, Member.
- 2007- European Hematology Association, Member.
- 2007- American Association for Cancer Research, Member.

Editorial Boards:

- 1999-2001 Editorial Board, Member, Bio-Oncology Watch.
- 2008- Ad Hoc Reviewer, Journal of Clinical Oncology.
- 2009- Ad Hoc Reviewer, Blood.
- 2001- Ad Hoc Reviewer, Clinical Cancer Research.
- 2001- Ad Hoc Reviewer, Lancet.
- 2002- Editorial Board, Member, Clinical Lymphoma Myeloma.
- 2009- Associate Editor, Clinical Lymphoma Myeloma.

Awards and Honors:

- 1981 Boston Globe Frances Burns Medical Scholarship Award.
- 1981 American Society of Microbiology Award.
- 1981 Westinghouse National Science Talent Search, Honors Group
- 1981 Bausch and Lomb Science Award.
- 1981-1985 Boston University Academic Scholar.
- 1985 Teaching Excellence Award, Educational Studies Program, Massachusetts Institute for Technology.
- 1985 Alpha Epsilon Delta (National Premedical Honor Society).

1989-1991 Culpepper Fellowship Award (3).
1989-1991 Mehos Fellowship Award for Cancer Research (3).
1991 Sigma Chi (National Research Honor Society).
1991 Grunebaum Fellowship Award for Cancer Research.
1991 New England Association for Cancer Research Award.
1991 Fellowship Award, International Association for
Comparative Research on Leukemia and Related Diseases.
1991 National Heart, Lung, Blood Institute Transfusion
Medicine Award.
1992 Alpha Omega Alpha (National Medical Honor Society).
1992 Citation from Commonwealth of Massachusetts for Science
Achievement.
1993 Wein Cancer Research Award.
1993 Citation from State Senate of the Commonwealth of
Massachusetts for Achievement in Medicine.
1997 Lauri Strauss Leukemia Foundation Fellowship Award.
1997 International Myeloma Foundation Fellowship Award.
1998 Young Investigator Award, American Society of Clinical
Oncology.
1998 First Place Award, National Medical Oncology Fellows Forum.
1999 Multiple Myeloma Research Foundation Fellowship Award.
2000 International Waldenstrom's Macroglobulinemia Foundation
Fellowship Award.
2002 Honorary Member of the Argentinian Hematology Society.
2004 International Waldenstrom's Macroglobulinemia Foundation
Achievement Award.
2005 Robert A. Kyle Award for Contributions to Waldenstrom's
Macroglobulinemia, 10th International Workshop on Multiple
Myeloma
2008 "Top Doctors", Best of Boston Award in Medical Oncology.

Research, Teaching, and Clinical Contributions

A. Narrative Report

My research, clinical and teaching activities are focused on Waldenstrom's Macroglobulinemia (WM), an incurable B-cell malignancy which effects 5-6,000 individuals a year in the United States. As part of these efforts, I helped define a familial form of this disease by describing its incidence, as well as clinicopathological characteristics. To further these efforts, my research team and I established a family registry which has recruited over 600 WM patients and their family members. These studies have led to important insights into the genetic basis of WM including the identification of increased incidence of hypogammaglobulinemia and monoclonal gammopathy in family members of patients with WM, and identification of mutations in genes predisposing to Common Variable Immunodeficiency Disorder (CVID) in WM patients. In order to determine the genetic basis of WM, my laboratory has been utilizing array cGH, microRNA and gene expression profiling studies of tumor and micro-environmental cells in WM, which have led to the identification of signaling pathways supportive of the growth and survival of WM cells. These efforts have also led to the identification of bone marrow mast cells (BMMC) as potent inducers of tumor cell growth in WM patients through interactions involving CD154-CD40, a pathway induced by tumor cell secretion of soluble CD27. These revelations have helped establish the importance of targeting mast cells and their tumor cell interactions in the treatment of WM, and have resulted in several clinical trials exploiting these findings. In addition, my laboratory has also focused on the development of novel therapeutics by exploiting gains made in our basic science understanding of WM, as well as predictive testing for the efficacy of such agents such as the use of polymorphisms in the CD16 receptor to predict responses to rituximab.

An important complement to my basic research efforts has been the conduct of dedicated clinical trials for WM patients. As part of these efforts, I organized the Waldenstrom's Macroglobulinemia Clinical Trials Group (WMCTG) which has conducted multi-center clinical trials utilizing monoclonal antibodies alone and in combination with nucleoside analogs, cytotoxic and immunomodulating agents, and the proteasome inhibitor bortezomib, as well as single agent studies with phosphodiesterase, stem cell factor and mTOR inhibitors. For most of these studies, I served as study chair and oversaw their development, patient recruitment, data collection and analysis, and reporting. In addition, my clinical research has led to the recognition of short and long term consequences of treatment endemic to WM patients: 1) rituximab-mediated IgM flare; 2) lenalidomide-related aggravated anemia; 3) increased bortezomib-related neuropathy risk; 4) nucleoside analogue related secondary malignancies. The findings of these studies have been published in major peer reviewed journals and have lead to changes in the published consensus approaches to the treatment of WM patients.

Lastly, the WM clinic which I founded at the Dana Farber Cancer Institute ten years ago continues to be the largest referral center in the world with 500-600 annual patient visits. The WM clinic has provided me with the opportunity to perform numerous intra- and extramural collaborative studies into the natural history, morbidity, genetic predisposition, and treatment of WM. I have used these experiences and studies to teach thousands of medical students, residents, physicians, allied health care givers, and scientists about the genetic basis, pathogenesis, and management of WM, and related plasma cell disorders, through bedside teaching, grand rounds, regional, national and international medical and scientific meetings.

B. Funding Information

2000-2005

National Institutes of Health K-23 (CA87977-01)

Role: PI

Novel Serotherapy Strategies for the Plasma Cell Malignancies

2000-2005

Research Fund for Waldenstrom's

Role: PI

Clinical Trial Funding for Waldenstrom's Macroglobulinemia

2000-2006

Genentech BioOncology

Role: PI

Phase II study of Extended Rituximab in Multiple Myeloma

Phase II Study of Extended Rituximab in Waldenstrom's Macroglobulinemia

Phase II Study of Fludarabine and Rituximab in Waldenstrom's Macroglobulinemia

2000-2006

Berlex Oncology Inc.

Role: PI

Phase II Study of Fludarabine and Rituximab in Waldenstrom's Macroglobulinemia

Phase II Study of Campath-1H in Waldenstrom's Macroglobulinemia

2000-2009

Waldenstrom's Cancer Fund

Role: PI

Cytogenetic Studies in Waldenstrom's Macroglobulinemia

2000-2012

Bailey Family Fund for Waldenstrom's Research

Role: PI

Studies into the Molecular Pathogenesis of Waldenstrom's Macroglobulinemia

2002-2009

Peter and Helen Bing Foundation

Role: PI
Basic and Clinical Studies into Waldenstrom's Macroglobulinemia

2003-2006
Celgene Corporation
Role: PI
Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Phase II Study of CC-5013 and Rituximab in Waldenstrom's Macroglobulinemia

2003-2008
Edward and Linda Nelson Foundation
Role: PI
Support for Basic Studies into Waldenstrom's Macroglobulinemia

2004-2008
Millenium Pharmaceuticals Inc.
Role: PI
Phase II Study of Velcade in Waldenstrom's Macroglobulinemia
Phase II Study of Velcade, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia.

2005-2006
Pfizer Pharmaceuticals Inc.
Role: PI
Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia

2005-2007
Novartis Pharmaceuticals Inc.
Role: PI
Phase II Study of Imatinib Mesylate in Waldenstrom's Macroglobulinemia

2006-2007
Edward and Marion Salzman Foundation
Role: PI
Fellowship Endowment for Studies in Waldenstrom's Macroglobulinemia

2006-2008
Karen Lee Sobol Foundation
Role: PI
Fellowship Endowment for Studies in Waldenstrom's Macroglobulinemia

2007-2010
International Waldenstrom's Macroglobulinemia Foundation
Role: PI
Studies into the Genetic Basis and Pathogenesis of Waldenstrom's Macroglobulinemia

2008-2009

Coyote Foundation Fund

Role: PI

Studies into the Genetic Basis of Waldenstrom's Macroglobulinemia.

C. Report of Current Research Activities

- | | |
|---|----|
| 1. Phase II Trial of Rituximab and Fludarabine in Waldentrom's | PI |
| 2. Phase II Trial of Bortezomib, Dexamethasone, Rituximab in WM | PI |
| 3. Phase II Trial of Imatinib Mesylate in WM | PI |
| 4. Phase II Trial of Simvastatin in WM | PI |
| 5. Characterization of Familial WM | PI |
| 6. Genetic Basis and Pathogenesis of WM | PI |
| 7. Molecularly based treatment strategies for WM | PI |

D. Report of Teaching

1. Local contributions

a. Medical School

1989-1991 Teaching Fellow in Medical Microbiology (MED ME 711).
Department of Microbiology, Boston University.
students: 20.
Preparation time: 4-6 hrs/week/semester
Contact time: 4 hrs/week/semester.

1998- Lecturer (Plasma Cell Disorders, HST 211), Harvard Medical School.
students: 30.
Preparation time: 20 hrs/semester.
Contact time: 2 hrs/semester.

b. Graduate School

1990-1995 Lecturer (Growth Control and Cell Transformation, MED ME 717).
Boston University School of Medicine.
students: 15.
Preparation time: 4 hrs/week/semester.

Contact time: 2 hrs/week/semester.

c. Local Invited (Teaching) Presentations:

- 1998 Advances in Myeloma.
Seminars in Hematology-Oncology, Massachusetts General Hospital.
Invited Lecturer.
Hematologists, Oncologists, Fellows in Training.
students: 50.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Advances in the Biology and Therapy of Multiple Myeloma.
Hematology-Oncology Grand Rounds, Beth Israel-Deaconess
Medical Center, Boston MA.
Invited Lecturer.
Hematologists, Oncologists, Fellows in Training.
students: 30.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Waldenstrom's Macroglobulinemia.
Hematology-Oncology Grand Rounds, Dana-Farber Cancer Institute.
Invited Lecturer.
Hematologists, Oncologists, Fellows in Training.
students: 30.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Overview of Waldenstrom's Macroglobulinemia.
Workshop for Visiting Spanish Oncologists/Hematologists, Dana
Farber Cancer Institute.
Boston, MA.
Invited Lecturer.
students: 30
Preparation time: 4 hours.
Contact time: 2 hours.
- 2006 Waldenstrom's Macroglobulinemia.
Hematology-Oncology Grand Rounds, Massachusetts General
Hospital.
Invited Lecturer.
Hematologists, Oncologists, Fellows in Training.
students: 30.
Preparation time: 4 hours.
Contact time: 1 hour.

- 2006 Genetic Basis and Pathogenesis of Waldenstrom's Macroglobulinemia.
Department of Pathology, Brigham and Women's Hospital.
Boston, MA.
Invited Lecturer.
students: 60
Pathologists, Residents, and Fellows in Training.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2006 Waldenstrom's Macroglobulinemia: An Overview of Clinical Trials, Current Status and Future Directions.
Franco-American Workshop on Plasma Cell Disorders, Dana Farber Cancer Institute.
Boston, MA.
Invited Lecturer.
students: 40
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Overview of Waldenstrom's Macroglobulinemia.
Multiple Myeloma Workshop, Dana Farber Cancer Institute.
Boston, MA.
Invited Lecturer.
students: 30
Preparation time: 4 hours.
Contact time: 2 hours.
- 2008 Genetic Basis, Pathogenesis and Treatment of Waldenstrom's Macroglobulinemia.
Hematology-Oncology Grand Rounds, Beth Israel Deaconess Medical Center.
Invited Lecturer.
Hematologists, Oncologists, Fellows in Training.
students: 30.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Overview of Waldenstrom's Macroglobulinemia.
Multiple Myeloma Workshop, Dana Farber Cancer Institute.
Boston, MA.
Invited Lecturer.
students: 30
Preparation time: 4 hours.
Contact time: 2 hours.

d. Continuing Medical Education:

- 2002 Monoclonal Antibody Therapy for B-Cell Malignancies.
Institute for Continuing Health Education
Boston, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2002 Challenging Cases in Hematology: Multiple Myeloma.
Network for Oncology Communication and Research.
New York, NY.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2002 Challenging Cases in Hematology: Multiple Myeloma.
Network for Oncology Communication and Research.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Challenging Cases in Hematology: Multiple Myeloma.
Network for Oncology Communication and Research.
Washington, DC.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Advances in Low Grade Non-Hodgkin's Lymphoma.
Health Sciences Center.
Las Vegas, NV.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2002 Hematologic Malignancies in 2012: An Expert Forum & Debate.
Annual Meeting of the American Society of Hematology.
Philadelphia, PA.
Invited Lecturer.
Preparation time: 12 hours.

Contact time: 1.5 hours.

- 2002 ASH Update in B-cell Malignancies.
Rocky Mountain Oncology Society.
Denver, CO.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1.5 hours.
- 2003 Emerging Issues in the Treatment of B-Cell Lymphoproliferative Disorders.
Health Science Center
Orlando, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Multiple Myeloma: Challenging Cases in Hematology.
Network for Oncology Communication and Research.
Las Vegas, NV.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Update on Progress into the Biology and Treatment of B-Cell Malignancies.
South Carolina Oncology Society.
Charleston, SC.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1.5 hours.
- 2003 Monoclonal Antibodies and their use in the Treatment of Hematologic Malignancies.
Health Science Center
La Jolla, CA
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2003 Evaluating Monoclonal Therapy for B-Cell Malignancies: Indolent Lymphoma.
Health Science Center
Las Vegas, NV.
Invited Lecturer.
Preparation time: 4 hours.

Contact time: 1.5 hours.

- 2003 A Celebration of Monoclonal Antibody Therapy:
Mechanism of Action and Resistance.
Harvard University.
Cambridge, MA.
Moderator and Lecturer.
Preparation time: 20 hours.
Contact time: 2 hours.
- 2003 Evaluating Monoclonal Therapy for B-Cell Malignancies.
Troy, MI.
Health Science Center
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2004 Evaluating Monoclonal Therapy for B-Cell Malignancies.
Health Science Center
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2004 Update on Current Therapeutic Options for the B-cell malignancies.
Las Vegas, Nevada.
Health Science Center
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2004 Monoclonal Antibody Therapy for B-Cell Malignancies.
Santa Barbara, CA.
Health Science Center
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2004 Cases and Controversies in Hematology.
American School of Oncology.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Cases and Controversies in Hematology.

- American School of Oncology.
New Haven, CT.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1.5 hours.
- 2004 Monoclonal Antibody Therapy for B-Cell Malignancies.
Oncology Education Continuum.
Metairie, LA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Update on Indolent Non-Hodgkin's Lymphoma.
Network for Oncology Communication and Research.
Miami, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Hematologic Malignancies: A Critical Review with the Experts.
Oncology Learning Center.
Ft Lauderdale, FL.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1 hour.
- 2005 Roadmap to the Treatment of Multiple Myeloma.
American School of Oncology.
Washington, DC.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 6 hours.
- 2005 Optimizing Therapy for CD20 Expressing B-Cell Malignancies.
Orange County Oncology Society.
Newport Beach, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2005 Roadmap to the Treatment of Multiple Myeloma.
American School of Oncology.
Pittsburgh, PA.
Invited Lecturer.
Preparation time: 4 hours.

Contact time: 6 hours.

- 2006 Advances in the Therapy of Multiple Myeloma and Waldenstrom's Macroglobulinemia.
American School of Oncology.
Ft Lauderdale, FL.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1.5 hours.
- 2006 ASH Update: Novel Therapeutic Approaches for the Treatment of B-cell Malignancies.
Oncology Education Continuum.
Cincinnati, OH.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2006 Challenging Cases in Geriatric Oncology: Multiple Myeloma.
American School of Oncology.
Ft. Lauderdale, FL.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1 hour.
- 2006 Update on Multiple Myeloma and Waldenstrom's Macroglobulinemia.
Oncology Highlights.
New York, NY.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1.5 hours.
- 2006 Update on Multiple Myeloma and Waldenstrom's Macroglobulinemia.
Oncology Highlights.
San Francisco, CA.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1.5 hours.
- 2006 Update on Multiple Myeloma and Waldenstrom's Macroglobulinemia.
Oncology Highlights.
Miami, FL.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1.5 hours.

- 2006 Advances in biologically based therapies for indolent Non-Hodgkin's lymphoma.
Oncology Education Continuum.

Bloomsburg, PA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1.5 hours.
- 2006 Advances in the Treatment of Multiple Myeloma and Waldenstrom's Macroglobulinemia.
Challenging Cases in Hematology, American School of Oncology.
San Francisco, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Biologically Based Therapies for the Treatment of Plasma Cell Malignancies.
Center for Biomedical Continuing Education.
Princeton, NJ.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Novel Therapies for the Plasma Cell Malignancies.
Center for Biomedical Continuing Education.
Presque Isle, ME.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Hematology Highlights: Multiple Myeloma.
American School of Oncology.
New York, NY.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2007 Advances in biologically based therapies for indolent Non-Hodgkin's lymphoma.
Center for Biomedical Continuing Education.
New Brunswick, NJ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.

- 2007 Hematology Highlights: Multiple Myeloma.
American School of Oncology.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Update on Multiple Myeloma.
Annual Meeting of the American School of Oncology.
Las Vegas, NV.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Hematology Highlights: Multiple Myeloma.
American School of Oncology.
Chicago, IL.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2007 Hematology Highlights: Multiple Myeloma.
American School of Oncology.
New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Hematology Highlights: Multiple Myeloma.
American School of Oncology.
San Francisco, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Center for Biomedical Continuing Education.
South Portland, ME.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in biologically based therapies for indolent Non-Hodgkin's lymphoma.
Center for Biomedical Continuing Education.

Sparta, NJ.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1.5 hours.

- 2007 Advances in biologically based therapies for indolent Non-Hodgkin's lymphoma.
Health Sciences Center.
Asheville, NC.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2007 Novel Agents in the Treatment of Multiple Myeloma.
Center for Biomedical Continuing Education.
Peabody, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2008 Frontline Treatment of Multiple Myeloma.
Oncology and Hematology Associates.
New London, CT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Frontline Treatment of Multiple Myeloma.
Harbor Medical Associates.
Boston, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Treatment of Multiple Myeloma.
Optimum Health Education.
Omaha, NE.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 ASH Update on Multiple Myeloma.
Hematology Highlights, Imedex.
Los Angeles, CA.
Moderator and Invited Lecturer.
Preparation time: 24 hours.

Contact time: 8 hours.

- 2008 ASH Update on Multiple Myeloma.
Hematology Highlights, Imedex.
New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Therapy in Multiple Myeloma.
Center Biomedical Continuing Education.
Poughkeepsie, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour
- 2008 Advances in the Therapy in Multiple Myeloma.
Center Biomedical Continuing Education.
West Reading, PA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Therapy in Multiple Myeloma.
Center Biomedical Continuing Education.
West Reading, PA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Therapy in Multiple Myeloma.
Center Biomedical Continuing Education.
Ft. Wayne, IN.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2009 ASH Update on Multiple Myeloma.
Hematology Highlights, Imedex.
New York, NY.
Invited Lecturer.
Preparation time: 16 hours.
Contact time: 1 hour.
- 2009 Advances in the Therapy in Multiple Myeloma.
Center Biomedical Continuing Education.

Flemington, NJ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

2009 ASH and IMW Update on the Treatment of Multiple Myeloma
Optimum Health
San Antonio, TX
Invited Lecturer
Preparation time: 8 hours.
Contact time: 1 hour.

e. Advisory/Supervisory Responsibilities:

- 1992-1995 Thesis Advisor, Masters in Medical Sciences Program.
Boston University Medical Center.
Boston, MA.
Served as thesis advisor to candidates for Masters Degree in Medical Sciences, and oversaw wet and dry lab thesis studies.
100 hours/year.
- 1999-2004 Laboratory Studies Advisor for Post-Doctoral Studies.
Jerome Lipper Multiple Myeloma Center.
Dana Farber Cancer Institute.
Boston, MA.
Served as laboratory advisor to post-doctoral fellows in Dr. Kenneth Anderson's laboratory, in which I helped conceptualize Research projects as well as direct basic science studies in multiple myeloma and Waldenstrom's macroglobulinemia.
160 hours/year
- 2000–present Associate Physician in Hematology/Oncology.
Brigham and Women's Hospital.
Boston, MA.
As an Attending Physician in the Hematology Oncology Service, I provide clinical guidance to medical residents and medical oncology/hematology fellows, and other health care providers who attend daily work rounds, as well as weekly seminars during which I provide lectures on general hematologic oncology, and more specialized lectures covering topics in the care of patients afflicted with B-cell malignancies.
240 hours/year

- 2004-present Laboratory Principal Investigator.
Bing Center for Waldenstrom's Macroglobulinemia.
Dana Farber Cancer Institute.
Boston, MA.
As the laboratory principal, I am responsible for advising and mentoring technicians, graduate students and post-doctoral fellows. These responsibilities have included directing students to research papers of interest that I have reviewed and analyzed with my laboratory investigators so as to support research study development and implementation. These efforts involved conceptualizing individual research studies, as well as mentoring students on data analysis and interpretation. I also routinely gave lectures on seminal basic science papers at weekly laboratory meetings, as well as provided guidance to graduate students and fellows in abstract and manuscript preparation, and poster and oral presentations.
1040 hours/year
- 2004-present Physician and Clinical Trials Principal Investigator.
Bing Center for Waldenstrom's Macroglobulinemia.
Dana Farber Cancer Institute.
Boston, MA.
Chair, Waldenstrom's Clinical Trials Group (WMCTG).
As principal for institutional and multicenter clinical trials, and Chair of the Waldenstrom's Macroglobulinemia Clinical Trials Group (WMCTG), I oversee and mentor clinical research coordinators and research fellows in the development and administration of treatment, translational and corollary studies. As part of these efforts, I lecture at weekly clinical meetings on topics of relevance to the conduct of clinical trials, and clinical care of patients affected by WM. In as well I provide input on data interpretation for ongoing studies, and guidance study reporting, abstract and manuscript preparation, and poster and oral presentations.
1040 hours/year

2. Regional, National or International Presentations

Regional

- 1999 Immunotherapy of Myeloma.
Hematology-Oncology Grand Rounds.
University of Vermont Medical Center.
Burlington, VT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's
Lymphoma.
Baystate Medical Center, Hematology/Oncology Grand Rounds.
Springfield, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2001 Treatment options in indolent Non-Hodgkin's Lymphoma.
Tumor Board, Eastern Maine Medical Center.
Bangor, ME.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non- Hodgkin's
Lymphoma.
Brown University Oncology Consortium Meeting.
Providence, RI.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy in B-cell Malignancies.
Hematology-Oncology Grand Rounds, Tufts New England Medical
Center.
Boston, MA
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy in B-cell Malignancies.

- Seminars in Hematology.
Boston Medical Center,
Boston, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy in B-cell Malignancies.
Vermont Cancer Consortium Annual Meeting.
Rutland, VT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy in B-cell Malignancies.
Department of Medicine Grand Rounds, Dartmouth-Hitchcock
Medical Center.
Dartmouth, NH.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy
Puget Sound Oncology Consortium
Seattle, WA
Invited lecturer
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Monoclonal Antibody Therapy for B-Cell Malignancies.
Seminars in Hematology Oncology, Boston VA Medical Center.
Boston, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 New Therapeutic Options in the Management of non-Hodgkin's
Lymphoma.
Grand Rounds, Brown University Cancer Center.
Providence, RI.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Non-Hodgkin's Lymphoma.
Department of Medicine Grand Rounds, Jordan Hospital.

- Plymouth, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Advances in the Therapy of Waldenstrom's Macroglobulinemia.
Grand Rounds, Millenium Pharmaceuticals.
Cambridge, MA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2005 Update on Therapy of Waldenstrom's Macroglobulinemia.
Lymphoma Research Foundation.
Boston, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 2 hours.
- 2005 Advances in the Biology and Therapy of Waldenstrom's
Macroglobulinemia.
Cancer Center Grand Rounds, St. Elizabeth's Hospital Cancer Center.
Boston, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Emerging Therapies for the Treatment of Multiple Myeloma and
Waldenstrom's Macroglobulinemia.
Department of Medical Oncology Grand Rounds, Yale Cancer Center.
New Haven, CT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Update on Biologically Based Therapies for the B-cell Malignancies.
Department of Medicine Grand Rounds, Maine Medical Center.
Portland, ME.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Genetic Basis, Pathogenesis and Treatment of Waldenstrom's
Macroglobulinemia.
Hematology Grand Rounds, Tufts New England Medical Center.
Boston, MA.

- Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Optimizing Therapy for CD20 expressing B-cell malignancies.
Department of Medicine Grand Rounds, Jordan Hospital.
Plymouth, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Optimizing Therapy for CD20 expressing B-cell malignancies.
Oncology Rounds, Seacoast Cancer Center.
Portsmouth, NH.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Genetic Basis, Pathogenesis and Treatment of Waldenstrom's
Macroglobulinemia.
Hematology Oncology Grand Rounds, Dartmouth Hitchcock Medical
Center.
Hanover, NH.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-
Hodgkin's Lymphoma.
Medical Oncology Grand Rounds, Roger Williams Medical Center.
Providence, RI.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-
Hodgkin's Lymphoma.
Medical Oncology Rounds, Mt. Auburn Hospital.
Cambridge, MA.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2006 Novel Therapies for the Plasma Cell Malignancies.
Medical Oncology Grand Rounds, Baystate Medical Center.
Springfield, MA.

- Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Cancer Center Rounds, William W. Backus Hospital.
Norwich, CT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Targeting CD20 in the Treatment of Indolent Non-Hodgkin's Lymphoma.
Hematology Oncology Rounds, St. Elizabeth's Medical Center.
Boston, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Hematology Oncology Rounds, Boston VA Medical Center.
Boston, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Grand Rounds, Yale University Cancer Center.
New Haven, CT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Introduction to Basic Immunology
Biogen IDEC, Inc.
Boston, MA.
Invited Lecturer.
Preparation time: 16 hours.
Contact time: 4 hours.

- 2008 Primary Therapy of Waldenstrom's Macroglobulinemia with Bortezomib, Dexamethasone, and Rituximab (BDR).
Grand Rounds, Yale University Cancer Center.
New Haven, CT.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 0.5 hour.
- 2008 Biological and Clinical Aspects of Waldenstrom's Macroglobulinemia with New Experimental Therapeutics.
Hematology/Oncology Grand Round, University of Massachusetts.
Worcester, MA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2008 Frontline Therapy of Multiple Myeloma.
Hematology/Oncology Grand Rounds, Caritas Good Samaritan Hospital.
Brockton, MA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 ASH Updates on Non-Hodgkin's Lymphoma.
Hematology/Oncology Grand Rounds, St. Francis Hospital and Medical Center.
Hartford, CT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Therapy in Multiple Myeloma.
Hematology/Oncology Rounds, York Hospital.
York, ME.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2008 States of Art Treatment of Waldenstrom's Macroglobulinemia.
Lymphoma Grand Rounds, Millenium Pharmaceuticals Inc.
Cambridge, MA.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.

- 2008 Optimizing Therapy in Multiple Myeloma.
Department of Medicine Rounds, Bridgton Hospital.
Bridgton, ME.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2009 Biology and Therapy of Waldenstrom's Macroglobulinemia
Yale University Cancer Center
New Haven, CT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2009 Biology and Therapy of Waldenstrom's Macroglobulinemia
University of Connecticut Cancer Center
Hartford, CT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- National**
- 1999 Northwestern University Consensus Conference on
Monoclonal Antibody Therapy for B-cell malignancies.
Kona, HI.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1.5 hours.
- 1999 Monoclonal antibody therapy in Waldenstrom's Macroglobulinemia.
National Institute of Health, Workshop on Waldenstrom's
Macroglobulinemia.
Bethesda, MD.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1.5 hours.
- 1999 Monoclonal antibody therapy in plasma cell malignancies.
Rituxan Investigators Meeting,
Seattle, WA.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.

- 1999 Monoclonal antibody therapy in plasma cell malignancies.
12th International Conference on Monoclonal Antibody Use in Cancer,
San Diego, CA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 1999 Monoclonal antibody therapy in B-cell disorders.
Northwestern University Consensus Conference.
Kona, HA.
Invited Lecturer and Moderator.
Preparation time: 12 hours.
Contact time: 4 hours.
- 1999 Targeting MUC1 in Multiple Myeloma.
American Society of Hematology Annual Meeting.
New Orleans, LA.
Invited Presentation based on Abstract Submission.
Preparation time: 6 hours.
Contact time: 15 minutes.
- 1999 Treatment of Waldenstrom's Macroglobulinemia.
International Waldenstrom's Macroglobulinemia Foundation.
St. Louis, MO.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2000 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's
Lymphoma.
Department of Medicine Grand Rounds, VA Medical Center.
Albany, NY.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2000 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's
Lymphoma.
Hematology-Oncology Seminar Series, New York Medical College,
NY.
Valhalla, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2000 Update on Plasma Cell Dyscrasias.

- Cleveland Clinic and Multiple Myeloma Research Foundation.
Cleveland, OH.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2000 Use of Rituximab in Non-Malignant Disorders.
Genentech Inc.
San Francisco, CA.
Moderator and Invited Lecturer.
Preparation time: 20 hours.
Contact time: 8 hours.
- 2000 Monoclonal Antibody Therapy of Waldenstrom's Macroglobulinemia.
American Society of Clinical Oncology Annual Meeting.
Invited Presentation based on Abstract Submission.
New Orleans, LA.
Preparation time: 6 hours.
Contact time: 15 minutes.
- 2000 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Hematology-Oncology Grand Rounds, Christiana Medical Center.
Wilmington, DE.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2000 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Texas Oncology Protocol Conference.
Dallas, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2000 Targeting CD20 in B-cell Malignancies.
Rituxan Investigators Conference.
Washington, DC.
Co-Chair and Invited Lecturer.
Preparation time: 80 hours.
Contact time: 16 hours.
- 2000 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.

- Hoosier Oncology Group Fall Conference.
Indianapolis, IN.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2000 Advances in Biological Therapy of Multiple Myeloma and Waldenstrom's Macroglobulinemia.
Cleveland Clinic Foundation, Hematology-Oncology Grand Rounds.
Cleveland, OH.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2000 Monoclonal Antibody Therapy of Waldenstrom's Macroglobulinemia.
Northwestern University Lurie Cancer Center Grand Rounds.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2000 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
University of Illinois Hematology/Oncology Grand Rounds.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2000 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Rush Presbyterian Medical Center, Hematology/Oncology Grand Rounds.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2000 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Cook County Hospital Hematology/Oncology Grand Rounds.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Hematology-Oncology Grand Rounds, Albany Medical Oncology.
Albany, NY.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Hematology Oncology Grand Rounds, SUNY at Stoney Brook Health Science Center.
Stony Brook, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non- Hodgkin's Lymphoma.
Hematology-Oncology Grand Rounds, St. Luke's Roosevelt Hospital.
New York, NY.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Medicine Grand Rounds, Long Island Jewish Hospital.
Long Island, NY.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Hematology-Oncology Grand Rounds, North Shore Medical Center.
Long Island, NY.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy in Waldenstrom's Macroglobulinemia.
Northwestern University Opinion Leaders Roundtable on Monoclonal Antibody Therapy.
Kona, HI.
Invited Lecturer.

- Preparation time: 4 hours.
Contact time: 1 hour.
- 2001 Development of novel biologically based therapeutics for Multiple Myeloma.
Mayo Clinic, Goldman Conference on Multiple Myeloma.
Jacksonville, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Hematology-Oncology Grand Rounds, Walter Reed Army Medical Center.
Washington, DC.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Hematology-Oncology Grand Rounds, Johns Hopkins Medical Center, Baltimore, MD.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Hematology-Oncology Grand Rounds, University of Mississippi. Jackson, MS.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's Lymphoma.
Department of Medicine Grand Rounds, Atlanta Medical Center. Atlanta, GA.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Rituximab in Non-Malignant Disorders.

- Conference on the Use of Rituximab in Non-Malignant Disorders.
Genentech BioOncology, Inc.
S. San Francisco, CA.
Moderator and Invited Lecturer.
Preparation time: 12 hours.
Contact time: 6 hours.
- 2001 Monoclonal Antibody Therapy of Indolent Non-Hodgkin's
Lymphoma.
Hematology-Oncology Grand Rounds, Henry Ford Hospital.
Detroit, MI.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Waldenstrom's Macroglobulinemia.
Annual Meeting of the Michigan Blood Club.
Detroit, MI.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non- Hodgkin's
Lymphoma.
Rocky Mountain Cancer Center.
Denver, CO.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Indolent Non- Hodgkin's
Lymphoma.
Grand Rapids Oncology Group Annual Meeting.
Grand Rapids, MI.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2002 CD20 directed therapy in Waldenstrom's Macroglobulinemia: Insights
into mechanisms of action and resistance.
Roundtable on Monoclonal Antibody Therapy, Northwestern
University Medical Center.
Maui, HI.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1 hour.

- 2002 Monoclonal Antibody Therapy in B-cell malignancies.
California Cancer Consortium Annual Meeting.
Napa, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy in B-cell malignancies.
Hematology-Oncology Grand Rounds, Emory University.
Atlanta, GA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Rituximab in Waldenstrom's Macroglobulinemia.
Annual Meeting of the American Society of Clinical Oncology.
Orlando, FL.
Invited speaker based on submission of abstract.
Preparation time: 6 hours.
Contact time: 0.5 hour.
- 2002 Monoclonal Antibody Therapy of B-cell Malignancies.
Hematology Oncology Grand Rounds, Holy Family Medical Center
Cancer Center.
Ft. Lauderdale, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy of B-cell Malignancies.
Hematology Oncology Grand Rounds, Good Samaritan Hospital.
Ft. Lauderdale, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy of B-cell malignancies.
Hematology Oncology Grand Rounds, Bayonet Point Cancer Center.
Ft. Lauderdale, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy of B-cell Malignancies.

- Hematology Oncology Grand Rounds, University of Alabama Medical Center.
Birmingham, AL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Novel therapies for Lymphoplasmacytic Malignancies.
1st Annual Conference on Targeted Therapies.
Washington, DC.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Antibody Therapy in Waldenstrom's Macroglobulinemia.
Conference on Monoclonal Antibody Therapy in Hematological Malignancies.
Houston, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy of B-cell malignancies.
Hematology Oncology Grand Rounds, Arizona Cancer Center.
Tucson, AZ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Advances in Waldenstrom's Macroglobulinemia.
Annual Patient Conference on Waldenstrom's Macroglobulinemia, Arizona WM Foundation.
Tucson, AZ.
Guest Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy of B-cell malignancies.
Hematology Oncology Grand Rounds, University of Maryland Greenebaum Cancer Center.
Baltimore, MD.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Update on the Treatment of Multiple Myeloma.
Leukemia and Lymphoma Society Patient Education Forum.

- Portland, OR.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Advances in the Treatment of Non-Hodgkin's Lymphoma.
Atlanta Cancer Care Center Hematology Oncology Rounds.
Atlanta, GA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Advances in the Treatment of Non-Hodgkin's Lymphoma.
25th Annual Topics in Medical Oncology Symposium, Baptist Hospital
East Cancer Center.
Louisville, KY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Advances in the Treatment of Non-Hodgkin's Lymphoma.
Hematology Oncology Grand Rounds, University of Louisville Cancer
Center.
Louisville, KY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Treatment of Waldenstrom's Macroglobulinemia.
Symposium on Multiple Myeloma and Related Plasma Cell Disorders,
Annual Meeting of the American Society of Hematology.
Philadelphia, PA.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 0.5 hour.
- 2002 Monoclonal Antibody Therapy for B-cell Malignancies.
Symposium, Annual Meeting of the American Society of Hematology.
Philadelphia, PA.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy.
Medical Oncology Grand Rounds, Penrose Cancer Center.

- Colorado Springs, CO.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy in B-cell malignancies.
Hematology-Oncology Grand Rounds, Memorial Sloan Kettering
Cancer Center.
New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy of B-cell malignancies.
Hematology Oncology Grand Rounds, Roswell Park Memorial
Institute.
Buffalo, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Advances in Waldenstrom's Macroglobulinemia.
Lymphoma/Myeloma Conference, Cornell University Medical School.
New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Advances in Waldenstrom's Macroglobulinemia.
Hematology Oncology Grand Rounds, St. Vincent's Medical Center.
New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy of B-cell malignancies.
Hematology Oncology Grand Rounds, SUNY Downstate Medical
Center.
Brooklyn, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Monoclonal Antibody Therapy for B-cell Malignancies.
Hematology Oncology Grand Rounds, Fox Chase Cancer Center.
Philadelphia, PA.

- Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Monoclonal Antibody Therapy for B-cell Malignancies.
Hematology Grand Rounds, University of Tennessee Medical Center.
Chattanooga, TN.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2003 Monoclonal Antibody Therapy for B-cell Malignancies.
Department of Medicine Grand Rounds, Erlanger Hospital.
Chattanooga, TN.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2003 Antibody Therapy for Waldenstrom's Macroglobulinemia.
Conference on Monoclonal Antibodies.
Naples, FL.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2003 Biology and Therapy of Waldenstrom's Macroglobulinemia.
Hematology Grand Rounds, Stanford University School of Medicine,
Palo Alto, CA.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2003 Progress on the Use of Monoclonal Antibodies in the Treatment of
Non-Hodgkin's Lymphoma.
Hematology Oncology Grand Rounds, University of Miami Cancer
Center.
Miami, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Waldenstrom's Macroglobulinemia: Update from the International
Workshop on WM.
Meet the Professor Session, Annual Meeting of the American Society
for Clinical Oncology.
Chicago, IL.

- Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2003 Treatment of Waldenstrom's Macroglobulinemia.
First Annual Conference: Targeted Therapies for the Treatment of
Hematological Malignancies.
Hualalai, HI.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Advances in the Treatment of Waldenstrom's Macroglobulinemia.
Pan Pacific Lymphoma Conference.
Kohala Coast, HI.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 ASCO Review: Advances in the Treatment of Non-Hodgkin's
Lymphoma.
National Meeting of the International Oncology Network.
Washington, DC.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Advances in the Treatment of Non-Hodgkin's Lymphoma.
Department of Medicine Grand Rounds, Vanderbilt University
Hospital.
Nashville, TN.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Advances in the Treatment of Non-Hodgkin's Lymphoma.
Tumor Board, Scripps Institute.
La Jolla, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Advances in the Treatment of Non-Hodgkin's Lymphoma.
BMT Rounds, University of California San Diego.
San Diego, CA.

- Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Evaluating Monoclonal Antibody Therapy for B-Cell Malignancies.
Department of Medicine Grand Rounds, University of Tennessee.
Knoxville, TN.
Moderator and Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Monoclonal Antibodies in the Treatment of B-Cell Malignancies.
Department of Medicine Grand Rounds, University of Michigan.
Ann Arbor, MI.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Monoclonal Antibodies and their use in the Treatment of Hematologic
Malignancies.
Department of Medicine Grand Rounds, Van Elsander Cancer Center.
Grosse Pointe Woods, MI.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2003 Monoclonal Antibodies in B-cell Malignancies: Mechanisms of Action
and Resistance.
Symposium, Annual Meeting of the American Society of Hematology.
San Diego, CA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2004 Basic Science and Laboratory Clues for the Treatment of
Waldenstrom's Macroglobulinemia.
Lymphoma/Myeloma 2004, Weill Medical College of Cornell
University.
New York, NY.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2004 Advances in the Biology and Treatment of Waldenström's
Macroglobulinemia.

- Northern California WM Support Group, International Waldenstrom's Macroglobulinemia Foundation.
Berkeley, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Advances in the Biology and Treatment of Waldenström's Macroglobulinemia.
Southern California WM Support Group, International Waldenstrom's Macroglobulinemia Foundation.
Los Angeles, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Multiple Myeloma: Novel Strategies and Therapeutics.
Oncology Rounds, New Mexico Cancer Center.
Albuquerque, NM.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Multiple Myeloma: Novel Strategies and Therapeutic.
Oncology Rounds, El Paso Community College Cancer Treatment Center.
El Paso, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Update on the Biology and Management of Waldenstrom's Macroglobulinemia.
Hematology-Oncology Grand Rounds, MD Anderson Cancer Center.
Houston, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 ASH Update: Lymphoma.
Seminars in Oncology, California Cancer Center.
Fresno, CA
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

- 2004 Waldenström's Macroglobulinemia: Clinicopathologic Definitions, Prognostic Markers, Treatment Recommendation.
Kaiser Permanente Hematology/Oncology Symposium.
Los Angeles, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Expanding Treatment Options for Indolent Non-Hodgkin's Lymphoma (NHL).
Medical Oncology Rounds, Huntsman Cancer Institute.
Salt Lake City, UT.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Expanding Treatment Options for Indolent Non-Hodgkin's Lymphoma (NHL).
Department of Medicine Grand Rounds, McKay Dee Hospital.
Ogden, UT.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2004 Expanding Treatment Options for Indolent Non-Hodgkin's Lymphoma (NHL).
Medical Oncology Rounds, USC/Norris Cancer Center.
Los Angeles, CA.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2004 Current and Future Use of Rituximab in B-cell Malignancies.
Annual Rituximab Investigators Meeting.
Hollywood, FL.
Meeting Co-Chair and Lecturer.
Preparation time: 40 hours.
Contact time: 16 hours.
- 2004 Advances in the Treatment of B-Cell Malignancies.
Grand Rounds, Tulane University Health Sciences Center.
New Orleans, LA.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.

- 2004 Waldenstrom's Macroglobulinemia.
Conference on Multiple Myeloma and Related Plasma Dyscrasias.
Los Angeles, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Prognostic Assessment and Treatment Strategies for B-Cell Malignancies.
Symposium, Annual Meeting of the American Society of Hematology.
San Diego, CA.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1 hour.
- 2004 Targeting B-cells in the Treatment of Immune Mediated Disease.
B-cell Summit.
Carlsbad, CA.
Moderator and Invited Lecturer.
Preparation time: 12 hours.
Contact time: 4 hours.
- 2005 Newer Approaches in the Treatment of Multiple Myeloma.
Department of Medicine Grand Rounds, Valley Hospital.
Paramus, NJ.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2005 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
St. Vincent's Hospital Cancer Center Grand Rounds.
New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Advances in the Treatment of B-cell Malignancies.
Annual Meeting of the Rocky Mountain Cancer Society.
Denver, CO.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2005 ASH Update: B-cell Malignancies.
Department of Medicine Grand Rounds, Penrose-St. Francis Hospital.
Colorado Springs, CO.

- Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Novel Therapies for B-cell Malignancies.
Leukemia and Lymphoma Society Physician Education Forum.
Fort Collins, CO.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Update on the Therapy of B-cell Malignancies.
Department of Medicine Grand Rounds, Boulder Community
Hospital. Boulder, CO.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Update on the Therapy of B-cell Malignancies.
Department of Medicine Grand Rounds, Sky Ridge Medical Center.
Lone Tree, CO.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2005 Advances in the Treatment of Waldenstrom's Macroglobulinemia.
Colorado WM Support Group, International Waldenstrom's
Macroglobulinemia Foundation.
Denver, CO.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2005 Advances in the Biology and Therapy of Waldenstrom's
Macroglobulinemia.
Focus on Myeloma and Plasma Cell Disorders.
Las Vegas, NV.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Advances in the Use of Monoclonal Antibody Therapy for the
Treatment of B-Cell Malignancies.
Department of Medicine Grand Rounds, City of Hope National
Medical Center.
Duarte, CA.

- Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Genetic Basis and Pathogenesis of Waldenstrom's
Macroglobulinemia.
Annual Meeting of the International Waldenstrom's
Macroglobulinemia Foundation.
Tampa, FL.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 2 hours.
- 2005 Basic Science and Clinical Advances on the Use of Monoclonal
Antibodies for the Treatment of Lymphoplasmacytic Malignancies.
Grand Rounds, Seattle Genetics.
Bothell, WA.
Invited Lecturer and Discussant.
Preparation time: 8 hours.
Contact time: 2 hours.
- 2005 Advances in the Biology and Therapy of Waldenstrom's
Macroglobulinemia.
Seattle WM Support Group, International Waldenstrom's
Macroglobulinemia Foundation.
Seattle, WA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 2 hours.
- 2005 New Developments in the Therapy of Waldenstrom's
Macroglobulinemia.
Meet the Professor Session, Annual Meeting of the American Society
for Clinical Oncology.
Orlando, FL.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 2 hours.
- 2005 Advances in the Treatment of Multiple Myeloma and Waldenstrom's
Macroglobulinemia.
Medical Oncology Grand Rounds, Hoag Cancer Center.
Newport Beach, CA.
Invited Lecturer.
Preparation time: 4 hours.

- Contact time: 1 hour.
- 2005 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Atlanta WM Support Group, International Waldenstrom's Macroglobulinemia Foundation.
Atlanta, GA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 2 hours.
- 2005 Optimizing Therapy for CD20 Expressing B-Cell Malignancies.
Medical Oncology Rounds, Wilford Hall Medical Center, Lackland AFB.
San Antonio, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Advances in the Therapy of B-Cell Malignancies.
University of Texas Health Science Center.
San Antonio, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Predicting Therapeutic Monoclonal Antibody Responses through Fcγ Receptor Polymorphisms.
Third Annual Conference on Therapeutic Advances in the Treatment of Hematological Malignancies.
Santa Monica, CA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2005 Monoclonal Antibodies in the Treatment of B-cell Malignancies.
Annual Oncology Retreat for Biogen-IDEC Inc.
Visiting Professor and Speaker.
Kauai, HI.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 2 hours.
- 2005 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Pan-Pacific Lymphoma Conference.

- Kauai, HI.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 0.5 hours.
- 2005 ASCO Update on B-Cell Malignancies.
Medical Oncology Rounds, Tulane University.
New Orleans, LA.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1.0 hour.
- 2005 Targeting B-Cells in the Treatment of Immune Diseases.
B-cell Summit.
Laguna Beach, CA.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 2.0 hours
- 2005 New Options in Waldenstrom's Macroglobulinemia.
Symposium, Annual Meeting of the American Society of Hematology.
San Diego, CA.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2005 Multicenter Study of Bortezomib in Waldenstrom's
Macroglobulinemia: Results of WMCTG Study 03-248.
Annual Meeting of the American Society of Hematology.
San Diego, CA.
Invited Speaker based on Abstract Submission.
Preparation Time: 8 hours.
Contact time: 0.5 hour.
- 2006 Advances in Biologically Based Therapies for B-cell Malignancies,
Annual Update Conference on Hematology Oncology, Penn State
Hershey Medical Center.
Hershey, PA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Diagnosis and Therapy of Waldenstrom's Macroglobulinemia.
Philadelphia WM Support Group Meeting, International
Waldenstrom's Macroglobulinemia Foundation.
Philadelphia, PA.

- Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Advances in the Biology and Therapy of Waldenstrom's
Macroglobulinemia.
Hematology Oncology Grand Rounds, Columbia University.
New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Advances in the Therapy of Multiple Myeloma and Waldenstrom's
Macroglobulinemia.
Department of Medicine Grand Rounds, New York Methodist
Hospital.
Brooklyn, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's
Macroglobulinemia.
Hematology/Oncology, Montefiore Medical Center.
Bronx, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 New Approaches for the Treatment of Waldenstrom's
Macroglobulinemia.
Lymphoma and Myeloma 2006.
New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Waldenstrom's Macroglobulinemia.
Hematology Oncology Rounds, Maimonides Medical Center.
Brooklyn, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

- 2006 Diagnosis and Therapy of Waldenstrom's Macroglobulinemia.
Sarasota WM Support Group Meeting, International Waldenstrom's
Macroglobulinemia Foundation.
Sarasota, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 2 hours.
- 2006 Genetic Basis, Pathogenesis and Treatment of Waldenstrom's
Macroglobulinemia.
Hematology Oncology Grand Rounds, MD Anderson Cancer Center.
Houston, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically Based Therapies for B-cell Malignancies.
Annual Meeting of the International Oncology Network.
Orlando, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Genetic Basis, Pathogenesis and Treatment of Waldenstrom's
Macroglobulinemia.
Focus on Myeloma and Plasma Cell Disorders.
Miami, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Update on Therapy of Plasma Cell Malignancies.
Best of ASCO Series, American Society of Clinical Oncology.
Reston, VA.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1 hour.
- 2006 Update on Therapy of Plasma Cell Malignancies.
Best of ASCO Series, American Society of Clinical Oncology.
Los Angeles, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

- 2006 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Virginia WM Support Group Meeting, International Waldenstrom's Macroglobulinemia Foundation.
Williamsburg, VA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Medical Oncology Grand Rounds, Stanford University Medical Center.
Stanford, CA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2006 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Chicago WM Support Group Meeting, International Waldenstrom's Macroglobulinemia Foundation,
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Update on Waldenstrom's Macroglobulinemia.
Department of Medicine Grand Rounds, Memorial Hospital.
Ft. Lauderdale, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Florida WM Support Group Meeting, International Waldenstrom's Macroglobulinemia Foundation.
Ft. Lauderdale, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Milton S. Hershey Medical Center College of Medicine.

- Hershey, PA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Department of Medicine Grand Rounds, Tulane University Medical Center.
New Orleans, LA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Defining the Road to the Cure in Waldenstrom's Macroglobulinemia.
Leukemia and Lymphoma Society Patient Education Forum.
San Francisco, CA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2007 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Medical Oncology Rounds, University of Texas Medical Branch.
Galveston, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Annual Meeting of the International Waldenstrom's Macroglobulinemia Foundation.
Atlanta, GA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Medical Oncology Fellow Rounds, Rush University Medical Center.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Hematology Oncology Rounds, University of Illinois at Chicago.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Medical Oncology Rounds, Baylor University Medical Center.
Dallas, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Dallas Area WM Support Group Meeting, Baylor University Medical Center.
Dallas, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Houston Area WM Support Group Meeting, MD Anderson Medical Center.
Houston, TX.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Oncology Grand Rounds, Washington Cancer Center.
Washington, D.C.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.

- Medical Oncology Grand Rounds, University of Nebraska Medical Center.
Omaha, NE.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Promising Directions in Myeloma and Lymphoproliferative Disorders. Symposium, Annual Meeting of the American Society of Hematology. Chicago, IL.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1 hour.
- 2007 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
New York WM Support Group Meeting, St. Vincent's Hospital. New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Waldenstrom's Macroglobulinemia and Multiple Myeloma: Diagnosis to Therapy.
Leukemia and Lymphoma Society Patient Education Forum. New York, NY.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 3 hours.
- 2008 Biology and Therapy of Waldenstrom's Macroglobulinemia.
Hematology Oncology Grand Rounds, Mt. Sinai School of Medicine. New York, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Progress in Waldenstrom's Macroglobulinemia.
Hematology Oncology Grand Rounds, Baylor Sammons Cancer Center. Dallas, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

- 2008 Update on the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Upstate New York WM Support Group Meeting, International Waldenstrom's Macroglobulinemia Foundation.
Rochester, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Frontline Therapy of Multiple Myeloma.
Hematology/Oncology Grand Rounds, Hackensack University Medical Center.
Lincoln Park, NJ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Update on the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Upstate New York WM Support Group Meeting, International Waldenstrom's Macroglobulinemia Foundation.
Rochester, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Optimizing Therapy of Multiple Myeloma.
Oncology Rounds, Center for Cancer and Hematologic Disease.
Cherry Hill, NJ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Novel Agents in the Treatment of Mutiple Myeloma.
Hematology Oncology Grand Rounds, Our Lady of Mercy Medical Center.
Bronx, NY.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2008 Novel Agents in the Treatment of Mutiple Myeloma.
Hematology Oncology Grand Rounds, Our Lady of Lourdes Medical Center.
Camden, NJ.
Invited Lecturer.

- Preparation time: 2 hours.
Contact time: 1 hour.
- 2008 Optimizing Therapy in Multiple Myeloma.
Seminars in Oncology, Oncology Hematology Specialists.
Morristown, NJ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour
- 2008 Changing Therapies in Multiple Myeloma.
Oncology/Hematology Grand Rounds, Nassau University Medical
Center.
East Meadow, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour
- 2008 Optimizing Therapy in Multiple Myeloma.
Seminars in Oncology, Oncology Hematology Specialists.
Morristown, NJ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour
- 2008 Frontline Therapy in Multiple Myeloma.
Hematology/Oncology Rounds, Berks Hematology Oncology
Regional Cancer Center.
West Reading, PA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour
- 2008 Update on Waldenstrom's Macroglobulinemia.
Philadelphia WM Support Group, Bryn Mawr Hospital.
Bryn Mawr, PA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Evolution and Revolution in the Management of Multiple Myeloma.
Great Debates in Hematology, Imedex.
Chicago, IL.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.

- 2008 Update on Waldenstrom's Macroglobulinemia.
North Texas WM Support Group, Baylor Sammons Medical Center.
Dallas, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Update on Waldenstrom's Macroglobulinemia.
Chicago Area WM Support Group, Lutheran General Hospital.
Chicago, IL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Treatment of Multiple Myeloma and Waldenstrom's
Macroglobulinemia.
Hematology Oncology Grand Rounds, University of Tennessee
Medical Center.
Memphis, TN.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Treatment of Multiple Myeloma and Waldenstrom's
Macroglobulinemia.
Hematology Oncology Grand Rounds, Arizona Cancer Center.
Tucson, AZ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Update on Lymphoma, Myeloma and Waldenstrom's
Macroglobulinemia.
Annual Hematology Oncology Review Course, Milton S. Hershey
Medical Center.
Hershey, PA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2008 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's
Macroglobulinemia.
Annual Meeting of the International Waldenstrom's
Macroglobulinemia Foundation.
Williamsburg, VA.

- Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Meet the Doctor: Update on Multiple Myeloma.
Leukemia and Lymphoma Society Patient Education Forum.
Portland, OR.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 3 hours.
- 2008 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's
Macroglobulinemia.
Hematology Oncology Grand Rounds, Oregon Health and Science
University.
Portland, OR.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Meet the Doctor: Update on Waldenstrom's Macroglobulinemia.
Leukemia and Lymphoma Society Patient Education Forum, Memorial
West Hospital.
Pembroke Pines, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 3 hours.
- 2008 Update on Waldenstrom's Macroglobulinemia.
Southern Florida WM Support Group, International Waldenstrom's
Macroglobulinemia Foundation.
Tampa, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Update on Waldenstrom's Macroglobulinemia and Multiple Myeloma.
Leukemia and Lymphoma Society Patient Education Forum.
Denver, CO.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Treatment of Waldenstrom's Macroglobulinemia and Multiple
Myeloma.

- Hematology/Oncology Grand Rounds, Rocky Mountain Cancer Center.
Denver, CO.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Treatment of Multiple Myeloma.
Hematology/Oncology Grand Rounds, Breslin Cancer Center, Michigan State University
Denver, CO.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
How Experts Treat Hematologic Malignancies Conference, City of Hope Cancer Center.
Kauai, HI.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2008 Novel Agents in the Treatment of Mutiple Myeloma.
Hematology Oncology Grand Rounds, University of Mississippi Medical Center.
Jackson, MS.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Hematology Oncology Grand Rounds, St. Vincent Oncology Center.
Indianapolis, IN.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Multiple Myeloma: Problems and Answers.
Annual Meeting of the Community Cancer Care Foundation.
Indianapolis, IN.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

- 2008 Advances in the Therapy in Multiple Myeloma.
Hematology/Oncology Rounds, University of Texas Health Science
Center.
San Antonio, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Advances in the Therapy in Multiple Myeloma.
Hematology/Oncology Rounds, University of Texas Health Science
Center.
San Antonio, TX.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2009 Primary Therapy of Multiple Myeloma.
US Oncology Hematology Oncology Practice Update
Albany, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2009 Treatment of Multiple Myeloma.
Kingston Hospital
Kingston, NY.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2009 Treatment of Multiple Myeloma.
Ellis Hospital Cancer Center Tumor Board
Schenectady, NY.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2009 Advances in the Biology and Therapy of Waldenstrom's
Macroglobulinemia.
Annual Hematology Reviews, University of Indiana
Indiannapolis, IN.
Invited Lecturer.
Preparation time: 16 hours.
Contact time: 1 hour.

- 2009 ASH Update: Multiple Myeloma and Waldenstrom's Macroglobulinemia.
Leukemia and Lymphoma Society Physician Forum
Ft. Lauderdale, FL
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1.5 hours.
- 2009 Advances in the Treatment of Multiple Myeloma and Waldenstrom's Macroglobulinemia.
Leukemia and Lymphoma Society Patient Forum
Ft. Lauderdale, FL
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 3 hours.
- 2009 Treatment of Multiple Myeloma.
Glens Falls Hospital Cancer Center Grand Rounds
Glens Falls, NY.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2009 Waldenstrom's Macroglobulinemia: Advances in Biology and Therapy
A Symposium in Honor of the Life and Contributions of Marvin Stone M.D.
Baylor Sammons Cancer Center
Baylor University
Dallas, TX.
Keynote Speaker.
Preparation time: 12 hours.
Contact time: 1 hour.
- 2009 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Moffit Cancer Center Grand Rounds
Tampa, FL.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.

International Presentations

- 1999 Monoclonal antibody therapy of plasma cell disorders.
VII International Conference on Malignant Lymphoma.
Lugano, Switzerland.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1.0 hour.
- 1999 Monoclonal antibody therapy in Multiple Myeloma.
VIth International Workshop on Multiple Myeloma.
Stockholm, Sweden.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1.5 hours.
- 2000 Advances in Treatment of Multiple Myeloma and Waldenstrom's
Macroglobulinemia.
1st Japanese-American Joint Conference on the Biology and Treatment
of Multiple Myeloma.
Tokyo, Japan.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 4 hours.
- 2001 Novel treatments in plasma cell disorders.
Advances in Hematological Malignancies and Supportive Care in
Cancer, 5th Annual Winter Oncology Conference.
Vancouver, BC, Canada.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2001 Novel Treatment Options in Waldenstrom's Macroglobulinemia.
1st International Symposium on Waldenstrom's Macroglobulinemia.
Banff, AB, Canada.
Chair and Invited Faculty.
Preparation time: 20 hours.
Contact time: 4 hours.
- 2001 Biology and Therapy of Waldenstrom's Macroglobulinemia.
VIIIth International Workshop on Multiple Myeloma.
Banff, AB, Canada.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 0.5 hours.
- 2001 Advances in the Treatment of Plasma Cell Disorders.

- 32nd Annual Nordic Hematology Meeting.
Vaasa, Finland.
Plenary Session Lecturer.
Preparation time: 20 hours.
Contact time: 1 hour.
- 2001 Monoclonal Antibody Therapy of Waldenstrom's Macroglobulinemia.
1st International Patient and Physician Summit on Waldenstrom's Macroglobulinemia.
Boston, MA.
Chair and Lecturer.
Preparation time: 80 hours.
Contact time: 18 hours.
- 2002 Treatment of Waldenstrom's Macroglobulinemia.
Advances in Hematological Malignancies and Supportive Care in Cancer, 6th Annual Winter Oncology Conference.
Vancouver, BC, Canada.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2002 Advances in the Biology and Treatment of Waldenstrom's Macroglobulinemia.
Annual Patient Conference of the International Waldenstrom's Macroglobulinemia Foundation.
Las Vegas, NV.
Invited Lecturer and Participant on Doctor's Panel.
Preparation time: 6 hours.
Contact time: 4 hours.
- 2002 Update on the use of Monoclonal Antibody Therapy in B-cell malignancies.
Annual Meeting of the International Oncology Network.
Scottsdale, AZ.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Biology and Therapy of Waldenstrom's Macroglobulinemia.
Workshop I.
VIIIth International Conference on Malignant Lymphoma.
Lugano, Switzerland.
Chair and Lecturer.
Preparation time: 12 hours.
Contact time: 2 hours.

- 2002 Advances in the Treatment of Multiple Myeloma.
32nd Annual Meeting of the Union International Contre de Cancer (UICC), Oslo, Norway
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2002 Advances in the Treatment of Lymphoplasmacytic Lymphoma.
2nd International Monoclonal Antibody Congress.
Banff, AB, Canada.
Session Moderator and Invited Lecturer.
Preparation time: 6 hours.
Contact time: 2 hours.
- 2002 Monoclonal Antibody Therapy of WM.
2nd International Workshop on Waldenstrom's Macroglobulinemia.
Athens, Greece.
Session Moderator and Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2002 Consensus Panels on Waldenstrom's Macroglobulinemia.
2nd International Workshop on Waldenstrom's Macroglobulinemia.
Athens, Greece.
Chair and Panel Moderator.
Preparation time: 120 hours.
Contact time: 40 hours.
- 2002 Treatment of Myeloma and Waldenstrom's Macroglobulinemia.
Annual Meeting of the Argentinian Hematology Society.
Buenos Aires, Argentina.
Keynote Speaker.
Preparation time: 12 hours.
Contact time: 3 hours.
- 2002 Waldenstrom's Macroglobulinemia.
Seminars in Medical Oncology, St. Bartholomew's Hospital.
London, United Kingdom.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Treatment of Waldenstrom's Macroglobulinemia.
2nd International Symposium on Waldenstrom's Macroglobulinemia.
IXth International Workshop on Multiple Myeloma.

- Salamanca, Spain.
Chair and Lecturer.
Preparation time: 40 hours.
Contact time: 2 hours.
- 2003 Monoclonal Antibody Therapy of Waldenstrom's Macroglobulinemia.
3rd International Monoclonal Antibody Congress.
Quebec City, Canada.
Co-Chair and Lecturer.
Preparation time: 40 hours.
Contact time: 8 hours.
- 2003 MabThera in Waldenström's Macroglobulinemia.
European Rituximab Investigator's Meeting.
Monte Carlo, Monaco.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2003 Novel agents in Waldenstrom's Macroglobulinemia.
2nd International Patient & Physician Summit on Waldenström's
Macroglobulinemia.
Los Angeles, CA.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2004 Monoclonal Antibodies in Indolent Non-Hodgkin's Lymphoma.
International Conference on Malignant Lymphoma.
San Juan, PR.
Moderator and Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2004 Waldenstrom's Macroglobulinemia.
North American Educational Forum on Lymphoma.
Lymphoma Research Foundation and Lymphoma Foundation Canada.
San Francisco, CA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 2 hours.
- 2005 Targeting CD20 in lymphoplasmacytic lymphoma.
International Workshop on Lymphoid Malignancies.
Laguna Beach, CA.
Invited Lecturer.

- Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Distinguishing Waldenstrom's Macroglobulinemia from other B-Cell Disorders.
Lymphoma: The Next Questions 2005.
San Juan, PR.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Diagnosis and Management of Waldenstrom's Macroglobulinemia.
Australia WM Support Group, International Waldenstrom's Macroglobulinemia Foundation.
Sydney, NSW, Australia.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Biology and Therapy of Waldenstrom's Macroglobulinemia.
10th International Workshop on Multiple Myeloma.
Sydney, NSW, Australia.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1 hour.
- 2005 Treatment of Waldenstrom's Macroglobulinemia.
3rd International Symposium on Waldenstrom's Macroglobulinemia.
Sydney, NSW, Australia.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2005 Nucleoside Analogues in the Treatment of Waldenstrom's Macroglobulinemia.
Nucleoside Analogues Experts Panel Meeting.
Geneva, Switzerland.
Moderator and Invited Lecturer.
Preparation time: 16 hours.
Contact time: 8 hours.
- 2005 Update on Waldenstrom's Macroglobulinemia.
North American Educational Forum on Lymphoma, Lymphoma Research Foundation and Lymphoma Foundation Canada.
Atlanta, GA.
Invited Lecturer.

- Preparation time: 4 hours.
Contact time: 2 hours.
- 2005 Novel Therapeutic Approaches with Rituximab.
Annual Meeting of the German Hematology Society.
Hannover, Germany.
Keynote Speaker.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2005 Diagnosis and Management of Waldenstrom's Macroglobulinemia.
37th Annual Course on Advances in Hematology, Imperial College.
London, United Kingdom.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 1 hour.
- 2005 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Department of Medicine Grand Rounds, University Hospital.
Munich, Germany.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 1.5 hours.
- 2005 Genetic Basis of Waldenstrom's Macroglobulinemia.
Symposium on the Advances in Biology and Therapy of Waldenstrom's Macroglobulinemia, 9th International Workshop on Malignant Lymphoma.
Lugano, Switzerland.
Chair and Lecturer.
Preparation time: 6 hours.
Contact time: 2.0 hours.
- 2005 Lymphoplasmacytic Lymphoma, Waldenstrom's Macroglobulinemia, and Splenic Marginal Zone Lymphoma-One disease?
WHO Classification Session, 9th International Workshop on Malignant Lymphoma.
Lugano, Switzerland.
Invited Lecturer.
Preparation time: 40 hours.
Contact time: 1 hour.
- 2005 Update on Multiple Myeloma.
Meet the Professor Session, 9th International Workshop on Malignant Lymphoma.

- Lugano, Switzerland.
Invited Lecturer.
Preparation time: 12 hours.
Contact time: 2.0 hours.
- 2005 Advances in the Biology and Therapy of Waldenstrom's
Macroglobulinemia.
IRCCS Policlinico.
San Matteo, Pavia, Italy.
Visiting Professor and Lecturer.
Preparation time: 6 hours.
Contact time: 2.0 hours.
- 2006 Diagnosis and Therapy of Waldenstrom's Macroglobulinemia.
International Workshop on Multiple Myeloma.
Mumbai, India.
Invited Lecturer.
Preparation time: 8 hours.
Contact time: 1 hour.
- 2006 Advances in Waldenstrom's Macroglobulinemia.
International Congress on Hematologic Malignancies.
Whistler, BC, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Genetic Basis and Treatment of Waldenstrom's Macroglobulinemia.
Toronto WM Support Group Meeting, International Waldenstrom's
Macroglobulinemia Foundation.
Toronto, ON, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Morbus Waldenstrom: Biology and Treatment, Istituto Oncologico
della Svizzera Italiana.
Medical Oncology Grand Rounds.
Bellinzona, Switzerland.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-
Hodgkin's Lymphoma.
Department of Medicine Grand Rounds, Universitatsspital.

- Basel, Switzerland.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Grand Rounds, Hopital Neuchatelois-La Chaux-de-Fonds.
Neuchatelois, Switzerland.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Grand Rounds, Universitatsspital Zurich.
Zurich, Switzerland.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Hematology/Oncology Rounds, Lausanne CHUV Hopital.
Lausanne, Switzerland.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Hematology/Oncology Grand Rounds, Kantonsspital.
Aarau, Switzerland.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Medical Grand Rounds, Universitatsspital.
Basel, Switzerland.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.

- 2006 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Seminars in Oncology, Tumorzentrum.
St. Gallen, Switzerland.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2006 Advances in Biologically-Based Therapies for Indolent Non-Hodgkin's Lymphoma.
Hematology/Oncology Rounds, Onkologieverein Espace-Mitteland.
Bern, Switzerland.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2006 Novel Therapies for the Plasma Cell Malignancies.
Annual Meeting of the Puerto Rico Oncology Society.
San Juan, PR.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Novel Agents and Approaches to the Treatment of Indolent Non-Hodgkin's Lymphoma.
Medical Oncology Grand Rounds, Sunnybrook Health Sciences Centre.
Toronto, ON, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Oncology Rounds, Princess Margaret Hospital.
Toronto, ON, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2006 Waldenstrom's Macroglobulinemia.
North American Educational Forum on Lymphoma, Lymphoma Research Foundation Annual Patient Conference.
Los Angeles, CA.
Invited Lecturer.
Preparation time: 4 hours.

- Contact time: 1 hour.
- 2007 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
International Congress on Hematologic Malignancies.
Whistler, BC, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Plasma Cell Disorders.
Clinical Advisors Meeting, World Health Organization.
Airlie, VA.
Session Chair and Invited Lecturer.
Preparation time: 16 hours.
Contact time: 3 hours.
- 2007 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Oncology Rounds, Princess Margaret Hospital.
Toronto, ON, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Hematology Oncology Grand Rounds, Queen Elizabeth II Hospital.
Halifax, NS, Canada.
Visiting Professor and Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Oncology Grand Rounds, Sunnybrook Hospital.
Toronto, ON, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2007 Advances in the Biology and Treatment of Waldenstrom's Macroglobulinemia.
Western Canadian Conference on B-cell Lymphoid Malignancies.
Banff, AB, Canada.
Invited Lecturer.

- Preparation time: 6 hours.
Contact time: 1 hour.
- 2008 Novel agents in Waldenstrom's Macroglobulinemia.
12th Annual International Congress on Hematologic Malignancies.
Whistler, BC, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1 hour.
- 2008 Waldenstrom's Macroglobulinemia.
13th Annual North American Educational Forum on Lymphoma,
Lymphoma Research Foundation.
San Francisco, CA.
Invited Lecturer.
Preparation time: 6 hours.
Contact time: 2 hours.
- 2008 Frontline Treatment of Waldenstrom's Macroglobulinemia.
International WM Advisory Board, Millenium Pharmaceuticals Inc.
Boston, MA.
Chair and Lecturer.
Preparation time: 12 hours.
Contact time: 4 hours.
- 2008 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's
Macroglobulinemia.
Oncology Grand Rounds, Jewish General Hospital.
Montreal, QB, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 2 hours.
- 2008 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's
Macroglobulinemia.
Oncology Grand Rounds, Ottawa General Hospital.
Ottawa, ON, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 2 hours.
- 2008 Update on Biology and Therapy of Waldenstrom's
Macroglobulinemia.
Ottawa Area WM Support Group Meeting, Ottawa General Hospital.
Ottawa, ON, Canada.

- Invited Lecturer.
Preparation time: 2 hours.
Contact time: 2 hours.
- 2008 Genetic Basis, Pathogenesis and Therapy of Waldenstrom's Macroglobulinemia.
Hematology Oncology Grand Rounds, Royal Victoria Hospital, McGill University.
Montreal, QB, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2008 Treatment of Waldenstrom's Macroglobulinemia.
Transplanter's Rounds, Hopital Maisonneuve-Rosemont.
Montreal, QB, Canada.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2008 Treatment of Waldenstrom's Macroglobulinemia.
Hematology Oncology Grand Rounds, Hopital Charles-Lemoyne.
Montreal, QB, Canada.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2008 Treatment of Waldenstrom's Macroglobulinemia.
Hematology Oncology Grand Rounds, Hopital Sacre-Coeur.
Montreal, QB, Canada.
Invited Lecturer.
Preparation time: 2 hours.
Contact time: 1 hour.
- 2008 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
Quebec Societè de Hematologie.
Montreal, QB, Canada.
Invited Lecturer.
Preparation time: 4 hours.
Contact time: 1.5 hours.
- 2008 Advances in the Biology and Therapy of Waldenstrom's Macroglobulinemia.
International Conference on Multiple Myeloma and other Monoclonal Gammopathies, European School of Hematology.

- Lisbon, Portugal.
 Invited Lecturer.
 Preparation time: 8 hours.
 Contact time: 1.5 hours.
- 2008 Intergrating Biomarkers in the Treatment of Non-Hodgkin's Lymphoma.
 23rd Nagoya International Cancer Treatment Symposium.
 Nagoya, Japan.
 Session Chair and Invited Guest Lecturer.
 Preparation time: 20 hours.
 Contact time: 3 hours.
- 2008 Bortezomib Based Therapiy in Waldenstrom's Macroglobulinemia.
 5th International Workshop on Waldenstrom's Macroglobulinemia
 Stockholm, Sweden.
 Lecturer.
 Preparation time: 6 hours.
 Contact time: 2 hours.
- 2008 Biology and Therapy of Waldenstrom's Macroglobulinemia.
 European Waldenstrom's Macroglobulinemia Patient Symposium
 5th International Workshop on Waldenstrom's Macroglobulinemia
 Stockholm, Sweden.
 Lecturer.
 Preparation time: 6 hours.
 Contact time: 6 hours.
- 2009 Novel Therapeutic Options in Waldenstrom's Macroglobulinemia.
 3rd International Patient and Physician Summit on Waldenstrom's
 Macroglobulinemia
 Boston, MA.
 Lecturer.
 Preparation time: 12 hours.
 Contact time: 2 hours.
- 2009 Genetic Basis and Pathogenesis of Waldenstrom's
 Macroglobulinemia.
 12th International Workshop on Multiple Myeloma
 Washington, D.C.
 Invited Speaker.
 Preparation time: 16 hours.
 Contact time: 1 hour.
- 2009 Genetic Basis, Predispositions and Pathogenesis of Waldenstrom's
 Macroglobulinemia.

3rd International Patient and Physician Summit on Waldenstrom's Macroglobulinemia
Boston, MA.
Lecturer.
Preparation time: 12 hours.
Contact time: 2 hours.

2009 Novel Therapeutic Options in Waldenstrom's Macroglobulinemia.
3rd International Patient and Physician Summit on Waldenstrom's Macroglobulinemia
Boston, MA.
Lecturer.
Preparation time: 12 hours.
Contact time: 2 hours.

4. Major curriculum offerings:

2000 Annual Rituximab Investigators Meeting.
Washington, DC.
Co-Organizer
Co-organized and developed the curriculum for this meeting with Dr. Ronald Levy, Stanford Medical Center, CA, which entailed an international conference on the use of the CD20 directed monoclonal antibody rituximab in the treatment of B-cell malignancies. As co-organizer, I prepared the topic list, discussion agendas, workshop breakout sessions, and was the principal moderator for this conference in which 180 international basic science and clinical experts on B-cell malignancies took part in this 2 day conference.

2001 1st International Symposium on Waldenstrom's Macroglobulinemia.
Banff, Canada.
Organizer and Chairperson.
Organized and developed the curriculum for this symposium which was held as part of the VIIIth International Workshop on Multiple Myeloma, and attracted 300 physicians and laboratory investigators, and covered the diagnosis, management and treatment of WM.

2001 1st International Summit on Waldenstrom's Macroglobulinemia.
Boston, MA.
Organizer and Chairperson.
Organized and developed the curriculum for this summit which brought together WM patients, and physicians with an expertise in WM for a 3

day summit during which WM patients attended lectures on the diagnosis, management and treatment of WM, as well as in depth analyses of WM case presentations by the experts. 200 hundred patients and 12 faculty members attended this summit.

- 2002 Workshop on Waldenstrom's Macroglobulinemia.
VIIIth International Conference on Malignant Lymphoma.
Lugano, Switzerland.
Organized and chaired this 2 hour workshop for the ICML. As chair and organizer, I prepared the curriculum, invited speakers, and moderated discussion for this workshop that focused on the biology and therapy of WM and attracted 500 attendees.
- 2002 2nd International Workshop on Waldenstrom's Macroglobulinemia.
Athens, Greece.
Co-organized this 3 day workshop on Waldenstrom's Macroglobulinemia with Drs. Robert Kyle and Meletios Dimopoulos. This 3 day conference attracted 50 international investigators with an expertise in WM. I oversaw the curriculum development for this conference and organized as part of this workshop 4 consensus panels, for which I organized the committees, consensus questions, teleconference transcripts, slide presentations for the consensus meetings and preparation of consensus manuscripts which defined the clinicopathological diagnosis, criteria to treat, treatment options and response criteria for WM. The consensus recommendations made by this panel were published in *Seminars in Oncology* and formed the basis for the current day management of WM. I also served as editor for the resulting proceedings of this meeting which were published in *Seminars in Oncology*, and oversaw peer review for the 20 WM related manuscripts that resulted from this meeting.
- 2003 2nd International Symposium on Waldenstrom's Macroglobulinemia.
Salamanca, Spain.
Organizer and Chairperson.
Organized and developed the curriculum for this symposium which was held as part of the IXth International Workshop on Multiple Myeloma, and attracted 300 physicians and laboratory investigators, and covered the diagnosis, management and treatment of WM.
- 2003 3rd International Monoclonal Antibody Congress.
Quebec, Canada
Co-Organizer

Co-organized this 2 day meeting of the Monoclonal Antibody Congress with Drs. Marvin Stone and Vinay Jain of Baylor Sammons Medical Center. As co-organizer, I helped prepare the curriculum and speaker selection, and served as a discussion moderator for this conference which attracted 150 international delegates.

- 2004 Annual Rituximab Investigators Meeting.
Hollywood, FL.
Co-Organizer
Co-organized with Dr. David Maloney, Fred Hutchinson Cancer Center this international conference of the use of the CD20 directed monoclonal antibody in the treatment of B-cell malignancies. Prepared topic list, agenda, workshop breakout sessions, and consensus panels addressing current and future use of rituximab in indolent and aggressive NHL. Two hundred international basic science and clinical experts on B-cell malignancies took part in this 2 day conference.
- 2004 3rd International Workshop on Waldenstrom's Macroglobulinemia.
Paris, France.
Co-organized this 3 day workshop on Waldenstrom's Macroglobulinemia with Drs. Jean Paul Ferman, Pierre Morel and Veronique LeBlond. This 3 day conference attracted 70 international investigators with an expertise in WM. I oversaw the curriculum development for this conference and organized as part of this workshop the consensus panels on treatment of WM, and response assessment. The consensus recommendations made by these panels were published in peer reviewed publications (Blood, Clinical Lymphoma Myeloma). I also served as editor for the resulting proceedings of this meeting which were published in Clinical Lymphoma Myeloma, and oversaw peer review for the 20 WM related manuscripts that resulted from this meeting.
- 2007 4th International Symposium on Waldenstrom's Macroglobulinemia.
Kos, Greece.
Organizer and Chairperson.
Organized and developed the curriculum for this symposium which was held as part of the Xth International Workshop on Multiple Myeloma, and attracted 300 physicians and laboratory investigators, and covered the diagnosis, management and treatment of WM.
- 2008 Workshop on Waldenstrom's Macroglobulinemia.
IXth International Conference on Malignant Lymphoma.

Lugano, Switzerland.

Organized and chaired this 2 hour workshop for the ICML. As chair and organizer, I prepared the curriculum, invited speakers, and moderated the panel discussion for this workshop that focused on the biology and therapy of WM and attracted 200 attendees.

2008 5th International Workshop on Waldenstrom's Macroglobulinemia.
Stockholm, Sweden.

Co-organized with Dr. Eva Kimby of the Karolinska Institute this 3 day workshop on Waldenstrom's Macroglobulinemia which attracted 90 international experts in WM. I oversaw the curriculum development for this conference, and organized as part of this workshop two consensus panels: Basic and Translational Science Priorities in WM; Treatment and Clinical Trial Priorities in WM. I also served as co-editor for the proceedings of this meeting which are forthcoming in Clinical Lymphoma Myeloma, and have overseen the peer review for the manuscripts that resulted from this meeting for this publication.

2009 3rd International Summit on Waldenstrom's Macroglobulinemia.
Boston, MA.

Organizer and Chairperson.

Organized and developed the curriculum for this Summit which brought together WM patients, and physicians and investigators with an expertise in WM for a 3 day summit during which WM patients attended lectures on the diagnosis, pathogenesis, clinical presentation and manifestations, management and treatment of WM, as well as in depth analyses of WM case presentations by experts. 600 patients and 40 faculty members attended the 3rd International Summit on WM.

E. Report of Clinical Activities

I oversee the Waldenstrom's Macroglobulinemia Clinic at the Dana Farber Cancer Institute which I founded ten years ago, and which continues to be the largest referral center in the world for WM with 500-600 annual patient visits. The WM clinic attracts patients throughout the United States, and ten percent of consultations are from abroad. More than half of patients to the WM clinic are referred by consultants. Included in these evaluations are opinions related to management of specific morbidities associated with WM including hyperviscosity, cold agglutininemia, cryoglobulinemia, amyloidosis, Bing Neel Syndrome, as well as IgM related autoimmune disorders such as IgM peripheral neuropathy. Most of the patients seen in the WM clinic enter studies evaluating the genetic basis, pathogenesis and treatment of WM. Given the high prevalence of familial disease, the WM Clinic also focuses on research into the genetic basis of WM. A registry of patients and families which is funded through the International Waldenstrom's Macroglobulinemia Foundation has recruited over 600 patients and family members through the WM clinic, and has served as the epicenter for both intra- and extramural efforts aimed at identifying the genetic basis and predispositions to WM.

The WM Clinic also offers patients access to a wide range of clinical research trials which are focused on the primary and salvage therapy of WM, as well as agents aimed at preventing disease progression in patients with asymptomatic disease. These include agents which have been validated in preclinical work performed in the Bing center for WM, and include monoclonal antibodies, immunomodulating agents, proteasome and phosphodiesterase inhibitors, cytokine modulators, statins, epigenetic modifiers, and MTOR signal inhibitors.

As part of the efforts of the WM clinic, I also provide teaching to patients, their family members, as well as to their providers and/or referring doctors on topics related to the diagnosis and management of this uncommon malignancy. In as well, I have precepted hematology oncology fellows, medicine residents, visiting physicians, and several times a year through the Bing Center Visting Professors Program, have held joint clinic sessions with prominent visiting professors who have come to advance their knowledge of this uncommon disorder.

Bibliography

Original Reports:

1. **Treon SP**, Fox ES, Broitman SA. Marine oils in the modulation of colonic flora and pH: Consideration for colonic cancer. *Micro Ecol Hlth Dis* 1989; 2:115-22.
2. **Treon SP**, Thomas P, Broitman SA. Lipopolysaccharide (LPS) processing by Kupffer cells releases a modified LPS with increased hepatocyte binding and decreased TNF- α stimulatory capacity. *PSEBM* 1992; 202(2):153-8.
3. **Treon SP**, Anand B, Chou IN, Broitman SA. Growth restraint and differentiation by LPS/TNF- α /INF- γ is accompanied by re-organization of the microtubule network in human leukemia cell lines. *Leukemia* 1992; 6:141-145.
4. **Treon SP**, Broitman SA. Beneficial effects of post-transfusional hepatitis in acute myelogenous leukemia may be mediated by lipopolysaccharides, tumor necrosis factor alpha and interferon-gamma. *Leukemia* 1992; 6: 1036-42.
5. **Treon SP**, Anand B, Ulevitch R, Broitman SA. CD14 mediated endogenous TNF -alpha release in HL60 AML cells: A potential model for CD14 mediated endogenous cytokine release in the treatment of AML. *Leukemia Res* 1994; 18:17-21.
6. Ogata A, Chauhan D, Urashima M, Teoh G, **Treon SP**, Anderson KC. Blockade of MAPK signaling in interleukin-6 independent multiple myeloma cells. *Clin Cancer Res* 1997; 3:1017-22.
7. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, **Treon SP**, Schlossman RL, Anderson KC. Interleukin-6 overcomes p21^{WAF1} upregulation and G1 growth arrest induced by dexamethasone and interferon in multiple myeloma cells. *Blood* 1997; 90:279-89.
8. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dederda DA, Hoshi Y, Teoh G, Ogata A, **Treon SP**, Chauhan D, Anderson KC. The development of a model for the homing of multiple myeloma cells to human bone marrow. *Blood* 1997; 90:745-65.
9. Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, **Treon SP**, Schlossman RL, Anderson KC. MDM2 protein overexpression promotes proliferation and survival of plasma cell leukemia cells. *Blood* 1997; 90:1982-92.

10. Chauhan D, Pandey P, Ogata A, Teoh G, **Treon SP**, Urashima M, Kharbanda S, Anderson KC. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. *Oncogene* 1997; 15:837-43.
11. Urashima M, Teoh G, Ogata A, Chauhan D, **Treon SP**, Sugimoto Y, Kaihara C, Matsuzaki M, Hoshi Y, DeCaprio JA, Anderson KC. Characterization of p^{16INK4A} expression in multiple myeloma and plasma cell leukemia. *Clin Cancer Res* 1997; 3:2173-9.
12. Urashima M, Teoh G, Ogata A, Chauhan D, **Treon SP**, Hoshi Y, DeCaprio JA, Anderson KC. Role of CDK4 and p16^{INK4A} interleukin-6 mediated growth of multiple myeloma. *Leukemia* 1997; 11:1957-63.
13. Ogata A, Chauhan D, Teoh G, **Treon SP**, Urashima M, Schlossman RL, Anderson KC. Interleukin-6 triggers cell growth via the Ras dependent mitogen activated protein kinase (MAPK) cascade. *J Immunol* 1997; 159:2212-21.
14. Urashima M, DeCaprio JA, Chauhan D, Teoh G, Ogata A, **Treon SP**, Hoshi Y, Anderson KC. p16^{INK4A} promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. *Blood* 1997; 90:4106-15.
15. Teoh G, Urashima M, Greenfield EA, Nguyen KA, Lee JF, Chauhan D, Ogata A, **Treon SP**, Anderson KC. The 86 kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. *J Clin Invest* 1998; 101:1379-1414.
16. **Treon SP**, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ, Anderson K.C., Anti-estrogens induce apoptosis of multiple myeloma cells. *Blood* 1998; 92:1749-1757.
17. **Treon SP**, Mollick JA, Chauhan DC, Urashima M, Teoh G, Ogata A, Raje N, Nadler L, Belch AR, Pilarski LM, Anderson KC. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. *Blood* 1999; 93:1287-1298.
18. Chauhan D, Bharti A, Raje N, Gustafson E, Pinkus GS, Pinkus JL, Teoh G, Hideshima T, **Treon SP**, Fingerroth JD, Anderson KC. Detection of Kaposi's sarcoma herpes virus DNA sequences in multiple myeloma bone marrow stromal cells. *Blood* 1999; 93:1482-1486.
19. Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, **Treon SP**, Webb IJ, Kufe D, Anderson KC. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpes virus gene sequences. *Blood* 1999; 93:1487-1495.
20. Chauhan D, Hideshima T, **Treon SP**, Teoh G, Raje N, Shima Y, Tai Y-T, Wei L, Fan J, DeCaprio J, Anderson KC. Functional interaction between retinoblastoma protein and stress activated protein kinase in multiple myeloma cells. *Cancer Res* 1999; 59:1192-1195.
21. **Treon SP**, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC. Treatment of plasma cell dyscrasias by antibody immunotherapy. *Semin Oncol* 1999; 26: 97-106.

22. Chauhan D, Hideshima T, Pandey P, **Treon SP**, Teoh G, Raje N, Rosen S, Krett N, Husson H, Avraham S, Kharbanda S, Anderson KC: RAFTK/PYK2-dependent and independent apoptosis in multiple myeloma cells. *Oncogene* 1999; 18:6733-40.
23. Teoh G, Tai Y-T, Urashima M, Shirahama S, Matsuzaki M, Chauhan D, **Treon SP**, Raje N, Hideshima T, Shima Y, Anderson KC. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. *Blood* 2000; 95:1039-46.
24. Tai Y-T, Teoh G, Shima Y, Chauhan D, **Treon SP**, Raje N, Hideshima T, Davies FE, Anderson KC. Isolation and characterization of human multiple myeloma cell enriched populations. *J Immunol Methods* 2000; 235:11-19.
25. Hideshima T, Chauhan D, Teoh G, Raje N, **Treon SP**, Tai T-Y, Shima Y, Anderson KC. Characterization of signaling cascades triggered by human IL-6 versus Kaposi's sarcoma associated herpesvirus encoded viral IL-6. *Clin Cancer Res* 2000; 6:1180-89.
26. Raje N, Kica G, Chauhan D, Zhang Y, Teoh G, **Treon SP**, Hideshima T, Tai Y-T, Pinkus GS, Pinkus JL, Skinner M, Comenzo RL, Anderson KC. Kaposi's sarcoma-associated herpes virus gene sequences are detectable at low copy number in primary amyloidosis. *Amyloid* 2000; 7:126-132.
27. **Treon SP**, Shima Y, Grossbard ML, Preffer FI, Belch AR, Pilarski LM, Anderson KC. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. *Ann Oncol* 2000; 11:107-111.
28. **Treon SP**, Anderson KC. The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. *Sem Oncol* 2000; 27:79-85.
29. **Treon SP**, Maimonis P, bua D, Young G, Raje N, Mollick J, Chauhan D, Tai YT, Shima Y, Hilgers J, von Mensdorff-Pouilly S, Belch AR, Pilarski LM, Anderson KC: Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. *Blood* 2000; 96:3147-53.
30. Chauhan D, Pandey P, Hideshima T, **Treon SP**, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, Kharbanda S, Anderson KC: SHP2 mediates the protective effect of interleukin-6 against dexamethasone induced apoptosis in multiple myeloma cells. *J Biol Chem* 2000; 275:27845-50.
31. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, **Treon SP**, Lin B, Schlossman RL, Richardson PG, Muller G, Stirling DI, Anderson KC: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. *Blood* 2000; 96:2943-50.
32. Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, **Treon SP**, Raje N, Hideshima T, Shima Y, Podar K, Anderson KC: Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. *J Immunol* 2000; 165:6347-55.
33. Davies FE, Raje N, Hideshima T, Lentzsc S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, **Treon SP**, Richardson PG, Schlossman RD, Morgan GJ, Muller GW, Stirling DI, Anderson KC: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. *Blood* 2001; 98:210-216.

34. **Treon SP**, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC: CD20 directed serotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom's Macroglobulinemia. *J Immunotherapy* 2001; 24:272-279.
35. **Treon SP**, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies. *J Immunotherapy* 2001; 24:263-271.
36. Mitsiades CS, **Treon SP**, Mitsiades N, Shima Y, Webb IJ, Anderson KC: TRAIL selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. *Blood* 2001; 98:795-804.
37. Gupta D, **Treon SP**, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic Applications. *Leukemia* 2001; 15:1950-61.
38. **Treon SP**, Belch AR, Kelliher A, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek A, Ellman L, Harmon D, Grossbard ML, Preffer FI, Pilarski LM, and Anderson KC: CD20-directed serotherapy in multiple myeloma: Biological considerations and therapeutic applications. *J Immunotherapy* 2002; 25:72-81.
39. Mitsiades N, Mitsiades C, Anderson KC, **Treon SP**. Intracellular regulation of TRAIL induced apoptosis in human multiple myeloma cells. *Blood* 2002; 99:2162-71.
40. Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, **Treon SP**, Anderson KC. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappaB B signaling. *Blood* 2002.
41. Mitsiades N, Mitsiades C, Poulaki V, Chauhan D, Famourakis G, Gu X, Bailey C, Joseph M, Libermann TA, **Treon SP**, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. *PNAS* 2002; 88:14374-9.
42. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, **Treon SP**, Munshi NC, Richardson PG, Anderson KC. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. *Oncogene* 2002; 21:5673-83.
43. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, **Treon SP**, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. *Blood* 2002; 99:4525-30.
44. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, **Treon SP**, Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic implications. *Blood* 2002; 99:4079-86.

45. Mitsiades N, Mitsiades C, Anderson KC, **Treon SP**. Resistance to tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is modulated by FLICE-inhibitory protein (FLIP) and procaspase-8 in multiple myeloma cells. *Blood* 2002; 100:3050-51.
46. **Treon SP**, Kelliher A, Keele B, Frankel S, Emmanouilides C, Kimby E, Byrd JC, Schlossman R, Mitsiades N, Mitsiades C, Preffer F, Anderson KC. Expression of serotherapy target antigens in Waldenström's Macroglobulinemia: therapeutic applications and considerations. *Semin Oncol* 2003; 30: 243-247.
47. Kriangkum J, Taylor BJ, Mant MJ, **Treon SP**, Belch AR, Pilarski LM. The malignant clone in Waldenström's Macroglobulinemia. *Semin Oncol* 2003; 30: 132-135.
48. Mitsiades CS, Mitsiades N, Richardson PG, **Treon SP**, Anderson KC. Novel biologically-based therapies for Waldenström's Macroglobulinemia. *Semin Oncol* 2003; 30: 309-312.
49. Mitsiades CS, Mitsiades N, **Treon SP**, Anderson KC. Proteomic analyses in Waldenström's Macroglobulinemia and other plasma cell dyscrasias. *Semin Oncol* 2003; 30:156-160.
50. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, **Treon SP**, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. *Cancer Res* 2003; 63:6689-96
51. Owen RG, **Treon SP**, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenström's Macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. *Semin Oncol* 2003; 30: 110-115.
52. Kyle RA, **Treon SP**, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, Lister TA, Merlini G, Morel P, Stone M, Branagan AR, Leblond V. Prognostic markers and criteria to initiate therapy in Waldenström's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. *Semin Oncol* 2003; 30: 116-120.
53. Gertz M, Anagnostopoulos A, Anderson KC, Branagan AR, Coleman M, Frankel S, Giralt S, Levine T, Munshi N, Pestronk A, Rajkumar V, and **Treon SP**. Treatment Recommendations in Waldenström's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. *Semin Oncol* 2003; 30:121-126.
54. Weber D, **Treon SP**, Emmanouilides C, Branagan AR, Byrd JC, Blade J, Kimby E. Uniform response criteria in Waldenström's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. *Semin Oncol* 2003; 30: 127-131.
55. Hayashi T, **Treon SP**, Hideshima T, Tai YT, Akiyama M, Richardson PG, Chauhan D, Grewal I, Anderson KC. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. *Br J Haematol* 2003; 121:592-596.

56. **Treon SP**, Branagan AR, Hunter Z, Santos D, Tournilhac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenström's Macroglobulinemia. *Ann Oncol* 2004; 15:1481-3.
57. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringarpure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, **Treon SP**, Munshi NC, Anderson KC. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. *Cancer Res* 2004; 64:2846-52.
58. Raje N, Hideshima T, Davies FE, Chauhan D, **Treon SP**, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC. Tumor cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. *Br J Haematol* 2004; 125:343-52.
59. Kriangkum J, Taylor BJ, **Treon SP**, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom Macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. *Blood* 2004; 104:2134-42.
60. **Treon SP**, Tournilhac O, Branagan AR, Hunter Z, Xu L, Hatjiharissi E, and Ditzel Santos D. Clinical Responses to Sildenafil in Waldenstrom's Macroglobulinemia. *Clin Lymph* 2004; 5:205-7.
61. **Treon SP**, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR. Extended rituximab therapy in Waldenström's Macroglobulinemia. *Ann Oncol* 2005; 16:132-8.
62. Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, **Treon SP**, Richardson P, Anderson KC. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. *Br J Haematol* 2005; 128:192-203.
63. **Treon SP**, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, and Fox EA. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical responses to Rituximab in Waldenstrom's Macroglobulinemia. *J Clin Oncol* 2005; 23: 474-81.
64. **Treon SP**, Hunter Z, Branagan AR. CHOP plus Rituximab therapy in Waldenstrom's Macroglobulinemia. *Clin Lymph* 2005; 5:273-277.
65. Hunter ZR, Branagan AR, Manning R, Patterson CJ, Santos DD, Tournilhac O, Dorfman DM, **Treon SP**, CD5, CD10, CD23 expression in Waldenstrom's Macroglobulinemia. *Clin Lymph* 2005; 5:246-9.
66. **Treon SP**, Morel P, LeBlond V, Femand JP. Report of the Third International Workshop on Waldenstrom's Macroglobulinemia. *Clin Lymph* 2005; 5:215-6.
67. Adamia S, **Treon SP**, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, Belch AR,

- Pilarski LM. Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's Macroglobulinemia. *Clin Lymphoma* 2005; 5:253-6.
68. Tassone P, Neri P, Kutok JL, Tournilhac O, Santos DD, Hatjiharissi E, Munshi V, Venuta S, Anderson KC, **Treon SP**, Munshi NC. A SCID-hu in vivo model of human Waldenstrom's Macroglobulinemia. *Blood* 2005; 106:1341-5.
69. Tai YT, Li XF, Catley L, Coffey R, Breikreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, **Treon SP**, Grewal IS, Munshi NC, Anderson KC. Immunomodulatory drug lenalidomide (CC-5013, ImiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. *Cancer Res* 2005; 65:11712-20.
70. **Treon SP**, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Santos DD, Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson CJ, Manning R, Branagan AR, Morton CC. Characterization of familial Waldenstrom's Macroglobulinemia. *Ann Oncol* 2006; 17: 488-94.
71. **Treon SP**, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, LeBlond V, Femand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ. Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. *Blood* 2006; 107:3442-6.
72. Kimby E, **Treon SP**, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Femand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ, Blade J. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. *Clin Lymphoma Myeloma* 2006; 6:380-3.
73. Martin SI, Marty FM, Fiumara K, **Treon SP**, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. *Clin Infect Dis* 2006; 43:16-24.
74. Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, **Treon SP**. Mast cells in Waldenstrom's Macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. *Ann Oncol* 2006; 17: 1275-82.
75. Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, anning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. *Clin Lymph Myeloma* 2006; 6:478-83.
76. Shamma MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R,

- Fulciniti M, Tai YT, **Treon SP**, Goyal RK. Specific killing of multiple myeloma cells by epigallocatechin-3-gallate extracted from green tea: biological activity and therapeutic implications. *Blood* 2006; 108: 2804-10.
77. Menke MN, Feke GT, McMeel JW, Branagan A, Hunter Z, **Treon SP**. Hyperviscosity-related retinopathy in Waldenstrom's Macroglobulinemia. *Arch Ophthalmol* 2006; 124: 1601-6.
78. Rodig SJ, Abramson JS, Pinkus GS, **Treon SP**, Dorfman DM, Dong HY, Shipp MA, Kutok JL. Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (Campath-1H). *Clin Cancer Res* 2006; 12: 7174-9.
79. Kriangkum J, Taylor BJ, Strachan E, **Treon SP**, Mant MJ, Reiman T, Belch AR, Pilarski LM. Molecular characterization of clonotypic VDJ sequences in Waldenstrom's Macroglobulinemia suggests independent transformation events in the development of biclonal B-cells. *Clin Cancer Res* 2007; 13: 2005-13.
80. Leleu X, O'Connor K, Ho A, Santos DD, Manning R, Xu L, Hatjiharissi E, Tournilhac O, Chemaly M, Branagan AR, Hunter ZR, Patterson CJ, Anderson KC, and **Treon SP**. Hepatitis C Viral Infection Is Not Associated with Waldenstrom's Macroglobulinemia. *Am J Hematol* 2006. *Am J Hematol* 2007; 82: 83-4.
81. **Treon SP**, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A. Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248. *Clin Cancer Res* 2007; 13:3320-5.
82. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Rabb MS, Xu L, **Treon SP**, Hideshima T, Anderson KC, Ghobrial IM. Protein kinase C inhibitor enzastaurin in vitro and in vivo antitumor activity in Waldenstrom's Macroglobulinemia. *Blood* 2007; 109: 4964-72.
83. Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock E, Ho A, Hunter ZR, Branagan AR, Patterson CJ, Kortsaris A, Verselis S, Fox E, **Treon SP**. Genetic linkage of Fc gammaRIIa and Fc gammaRIIIa and implications for their use in predicting clinical responses to CD20 directed monoclonal antibody therapy. *Clin Lymphoma Myeloma* 2007; 7: 286-90.
84. Kriangkum J, Taylor BJ, **Treon SP**, Mant MJ, Reiman T, Belch AR, Pilarski LM. Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. *Clin Cancer Res*. 2007; 13: 2005-13.
85. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Z, Zeismer S, Cabela M, Nehme A, Jia A, Moreau AS, **Treon SP**,

- Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM. Proteomic analysis of Waldenstrom Macroglobulinemia. *Cancer Res* 2007; 8: 3777-84.
86. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, **Treon SP**. Increased natural killer cell expression of CD16 and augmented binding and ADCC activity to rituximab among individuals expressing the Fc gamma RIIIA-158 V/V and V/F polymorphism. *Blood* 2007; 110:2561-4.
87. Santos DD, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly M, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi, **Treon SP**. Establishment of BCWM.1 cell line for Waldenstrom's Macroglobulinemia with productive *in vivo* engraftment in SCID-hu mice. *Exp Hematol* 2007; 35: 1366-75.
88. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, **Treon SP**, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. *Blood* 2007; 110: 4417-26.
89. Moreau AS, Jia X, Leleu X, Patterson CJ, Roccaro A, Xu L, Sacco A, O'Connor K, Soumerai J, Adamia S, hai NT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, **Treon SP**. The HGM-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom's Macroglobulinemia. *Br J Haematol* 2008; 142: 75-85.
90. Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteur V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, **Treon SP**, Facon T, Gertz MA, Ghobrial IM. Serum immunoglobulin free light chain correlates with tumor burden in Waldenstrom macroglobulinemia. *Leuk. Lymphoma* 2008; 49: 1104-7.
91. Roccaro AM, Leleu X, Moreau AS, Patterson, CJ, Xu L, Jia X, Ngo H, Sacco A, Cao Y, Ciccarelli B, Manning RJ, Adamia S, Hatjiharissi E, Russo D, Vacca A, Dammacco F, Ghobrial IM, **Treon SP**. Resveratrol exerts antiproliferative effects and induces apoptosis in Waldenstrom's Macroglobulinemia. *Clin Cancer Res* 2008; 14: 1849-58.
92. Leleu X, Eeckhoutte J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, **Treon SP**, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF-kappaB in Waldenstrom macroglobulinemia. *Blood* 2008; 111: 5068-77.
93. Moreau AS, Sebti Y, Duhamel A, Roccaro AM, Coiteux V, Gastinne T, Le Fric G, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, **Treon SP**, Facon T, Zorn E, Leleu X. Clinical relevance of soluble HLA class I

molecules in Waldenstrom macroglobulinemia. *Eur J Haematol* 2008; 80: 503-9.

94. Menke MN, Feke GT, McMeel JW, **Treon SP**. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. *Invest Ophthalmol Vis Sci* 2008; 49: 1157-60.
95. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, **Treon SP**, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. *Blood* 2008; 111: 4752-63.
96. Ho AW, Hatjiharissi E, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning R, Santos DD, Chemaly M, Ciccarelli B, Patterson CJ, Soumerai J, Munshi NC, McEarchern JA, Law CL, Grewal IS, and **Treon SP**. CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia. *Blood* 2008; 112: 4683-9.
97. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Moreau AS, Adamia S, Patterson CJ, Ghobrial IM, **Treon SP**. Increased incidence of Transformation and Myelodysplasia/Acute Leukemia in patients with Waldenstrom's Macroglobulinemia treated with Nucleoside Analogues. *J Clin Oncol* 2009; 27: 250-5.
98. **Treon SP**, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis T, Briccetti FT, Pasmantier M, Zimble H, Cooper RB, Moore M, Hill II J, Rauch A, Garbo L, Chu L, Chua C, Nantel SH, Lovett DR, Boedeker H, Sonneborn H, Howard J, Musto P, Ciccarelli BT, Anderson KC, Hatjiharissi E. Thalidomide and Rituximab in Waldenstrom's macroglobulinemia. *Blood* 2008; 112: 4452-7.
99. **Treon SP**, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis T, Chu L, Musto P, Baron AD, Nunnink JC, Kash JJ, Terjanian TO, Hyman PM, Nawfel EL, Sharon DL, Anderson KC. Lenalidomide and Rituximab in Waldenstrom's macroglobulinemia. *Clin Cancer Res* 2008; 15:355-60.
100. **Treon SP**, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister TA, Morel P, Matous J, Gregory SA, Kimby E. Long term outcomes to Fludarabine and Rituximab in Waldenström's macroglobulinemia. *Blood* 2009; 113: 3673-8.
101. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, **Treon SP**. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. *Blood* 2009; 113: 626-34.
102. Adamia, Reichert AA, Kuppusamy H, Kriangkum J, Ghosh A, Hodges JJ, Pilarski PM, **Treon SP**, Mant MJ, Reiman T, Belch AR, Pilarski LM. Inherited and acquired

variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom's macroglobulinemia. *Blood* 2008; 112: 5111-21.

103. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, LeBlond V, Femand JP, Merlini G, Morel P, Morra E, Owen R, Ghobrial IM, Seymour JF, Kyle RA, **Treon SP**. Update on treatment recommendations from the fourth international workshop on Waldenstrom's macroglobulinemia. *J Clin Oncol* 2008; 27:120-6.
104. Roccaro AM, Ghobrial IM, Treon SP, Malagola M, Anderson KC, Richardson PG, Russo D. Advances in the treatment of monoclonal gammopathies: The emerging role of targeted therapy in plasma cell dyscrasias. *Biologics* 2008 2 (3): 419-31
105. Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Sheehy P, **Treon SP**. Comparative outcomes following CP-R, CVP-R and CHOP-R in Waldenstrom's Macroglobulinemia. *Clin Lymphoma Myeloma* 2009; 9:62-6.
106. Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Liu X, Tseng H, Gong P, Sun J, Zhou Y, **Treon SP**. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced flare, as well as by plasmapheresis, in patients with Waldenstrom's Macroglobulinemia. *Clin Lymphoma Myeloma* 2009; 9:56-8.
107. **Treon SP**, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen MA, Matous J, Mattern II J, Diener J, Keogh G, Myers TJ, Birner A, Boral A, Esseltine DL, and Ghobrial IM. Primary therapy of Waldenstrom's Macroglobulinemia with Bortezomib, Dexamethasone and Rituximab: Results of WMCTG Clinical Trial 05-180. *J Clin Oncol* 2009; in press.
108. Leleu X, Tamburini J, Roccaro A, Morel P, Soumerai J, Levy V, Wemeau M, Balkaran S, Poulain S, Hunter ZR, Ghobrial IM, **Treon SP**, Leblond V. Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analogue-based therapy. *Clin Lymphoma Myeloma* 2009; 9: 71-3.
109. Menke MN, Feke GT, McMeel JW, **Treon SP**. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstrom's Macroglobulinemia. *Clin Lymphoma Myeloma* 2009; 9: 100-3.
110. Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, **Treon SP**. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. *Br J Haematol* 2009; 145: 59-63.

111. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia Sanz R, **Treon SP**, Leblond V, Kyle RA, Barlogie B, Merlini G. International prognostic scoring system for Waldenstrom Macroglobulinemia. *Blood* 2009; 113: 4163-70.
112. **Treon SP**. How I Treat Waldenstrom's macroglobulinemia. *Blood* 2009; 114(12): 419-31.
113. Hunter ZR, Manning RJ, Hanzis C, Ciccarelli BT, Ioakimidis L, Patterson CJ, Tseng H, Gong P, Liu X, Zhou Y, Yang G, Sun J, Xu L, Sheehy P, Morra M, **Treon SP**. IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia. *Haematologica* 2009; [epub ahead of print]
114. Ghobrial I, Hong F, Padmanabhan S, badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson K, Richardson P, **Treon SP**, Weller E, Matous J. Phase II of weekly bortezomib in combination with rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. *Journal of Clinical Oncology* 2010; [epub ahead of print]
115. Ghobrial I, Gertz M, LaPlant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell S, DeAngelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson K, Richardson P, **Treon SP**, Witzig T. Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. *Journal of Clinical Oncology* 2010; [epub ahead of print]

Reviews, Chapters and Editorials:

1. **Treon SP**, Broitman SA. Monoclonal antibody therapy in the treatment of Reyes Syndrome. *Med Hypoth* 1992; 39:238-42.
2. **Treon SP**, Chabner BA. Concepts in use of High-dose Methotrexate Therapy. *Clinical Chem* 1996; 42:1322-9.
3. **Treon SP**, Anderson KC, Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. *Current Opinion Hematology*. Philadelphia: Rapid Science Publishers, 1998; 5:42-48.
4. **Treon SP**, Raje N, Anderson KC: Immunotherapeutic strategies for the treatment of plasma cell malignancies. *Semin Oncol* 2000; 27:598-613.
5. Mitsiades N, Mitsiades C, Poulaki V, Anderson KC, **Treon SP**. Concepts in the use of TRAIL/Apo2L: An emerging biotherapy for myeloma and other neoplasias. *Exp Opinion* 2001; 10: 1-11.
6. **Treon SP**, Dimopoulos M, Kyle RA. Defining Waldenstrom's Macroglobulinemia. *Semin Oncol* 2003; 30: 107-109.
7. Merlini G, **Treon SP**. Waldenstrom's Macroglobulinemia. In: *Multiple Myeloma and Related Disorders*, 2nd ed., pgs. 429-51, Gahrton, Durie and Samson, eds., Arnold Publishing, London, 2004.
8. Getz MA, Merlini G, **Treon SP**. Amyloidosis and Waldenstrom's Macroglobulinemia. *Hematology (Am Soc Hematol Educ Program)* 2004; 257-82.
9. Dimopoulos MA, Kyle RA, Anagnostopoulos A, **Treon SP**. Diagnosis and Management of Waldenstrom's Macroglobulinemia. *Proc Am Soc Clin Oncol*. 2005; 23:1564-77.
10. Menke MN, **Treon SP**. Hyperviscosity Syndrome. In: *Clinical Malignant Hematology*, pgs. 937-41, Sekeres, Kalaycio, Bolwell eds., McGraw Hill Publishing, New York, 2007.

11. **Treon SP**, Leleu X, Evdoxia Hatjiharissi E, Moreau AS, Roccaro A, Hunter ZR, Soumerai J, Ciccarelli B, Xu L, Sacco A, Hai NT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial IM. Novel agents in the treatment of Waldenstrom's Macroglobulinemia. *Clin Lymphoma Myeloma* 2007; 7:199-206.
12. **Treon SP**, Hatjiharissi E, Merlini G. Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma. In: *Rare Hematological Malignancies*, pgs. 211-242, Stephen M. Ansell editor, Springer Publishers, 2008.
13. **Treon SP**, Giampaolo M. Waldenstrom's Macroglobulinemia and Cryoglobulinemia. In *Hematology: Principles and Practice*, Fifth edition. Elsevier Churchill Livingstone, Philadelphia, 2008.
14. **Treon SP**, Patterson CJ, Kimby E, Stone MJ. Advancements in the biology and treatment of Waldenstrom's Macroglobulinemia: A Report from the 5th International Workshop on Waldenstrom's Macroglobulinemia, Stockholm, Sweden. *Clin Lymphoma Myeloma* 2009; 9: 10-15.
15. **Treon SP**, Merlini G. Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia. In: *Noo-Hodgkin Lymphomas*, 2nd ed., C-14: pgs. 217-231, Armitage, Mauch, Harris, Coiffier and Dalla-Favera eds., Lippincott Williams & Wilkins, Philadelphia, PA 2010.
16. **Treon SP**, Merlini G. Macroglobulinemia. In: *Williams Hematology*, 8th ed., C-111: pgs. 1-13, Kaushansky, Lichtman, Beutler, Kipps, Seligsohn and Prchal. eds., McGraw-Hill Companies, New York City, NY 2010.

Abstracts (selected):

1. Ho A, Hatjiharissi E, Branagan A, Hunter Z, McEarchern J, Law C, Grewal I, Santos D, Tai Y, **Treon SP**. Therapeutic targeting of CD70 and CD27-CD70 interactions with the monoclonal antibody SGN-70 in Waldenstrom's Macroglobulinemia (WM). Proc Am Soc Clin Oncol. 2006; 24: 102s.
2. Hunter Z, Boxer M, Kahl B, Patterson C, Soumerai J, **Treon SP**. on behalf of the WMCTG. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079. Proc Am Soc Clin Oncol 2006; 24: 427s.
3. Patterson CJ, Soumerai J, Hunter Z, X. Leleu, Ghobrial I, **Treon SP**. Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. Proc Am Soc Clin Oncol 2006 26:435s.
4. **Treon SP**, Soumerai JD, Patterson CJ, Hunter ZR, Ghobrial IM, Villarreal R, Willen MA, Myers TJ. Bortezomib, Dexamethasone and Rituximab (BDR) is a highly active regimen in the primary therapy of Waldenstrom's macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180. Blood 2006; 108: 2765.
5. **Treon, SP**, Soumerai JD, Patterson CJ, Hunter ZR, Villarreal R, Ghobrial I. Imatinib Mesylate (Gleevec®) is active in relapsed/refractory Waldenstrom's Macroglobulinemia: Planned interim results of WMCTG Clinical Trial 05-140. Blood 2006; 108: 2484.
6. Hatjiharissi E, Ho AW, O'Connor K, Hunter ZR, Santos DD, Manning R, Leleu X, Moreau AS, Patterson CJ, McEarchern J, Law C, Grewal I, Munshi N, **Treon SP**. Preclinical *In Vitro* and *In Vivo* Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenstrom's Macroglobulinemia (WM). Blood 2006; 108: 2490.
7. Kriangkum J, Taylor BJ, **Treon SP**, Mant MJ, Reiman T, Belch AR, Pilarski LM. Molecular Characterization of Clonotypic VDJ Sequences in Waldenstrom's Macroglobulinemia Suggests Independent Transformation Events in the Development of Biclinal B Cells. Blood 2006; 108: 4624.
8. Patterson CJ, Moreau AS, Leleu X, Soumerai J, Hunter Z, Hatjiharissi E, Xu L, **Treon SP**. Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom's Macroglobulinemia (WM). Blood 2006; 108: 4749.

9. Jia X, Leleu X, Moreau AS, Ngo H, O'Sullivan G, McMillin D, **Treon SP**, Mitsiades C, Hideshima T, Palladino M, Anderson KC, Chauhan D, Ghobrial IM. The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. *Blood* 2006; 108: 4746.
10. Adamia S, Hodges J, Pilarski P, **Treon SP**, Mant M, Reiman T, Belch A, Pilarski LM. Accumulation of Inherited and Acquired Mutations in Hyaluronan Synthase1 Gene May Contribute Oncogenesis in Multiple Myeloma and Waldenstrom's Macroglobulinemia. *Blood* 2006; 108: 3432.
11. Ngo H, Hatjiharrissi E, Leleu X, Runnels J, Moreau AS, Jia X, O'Sullivan G, Santos DD, Xu L, **Treon SP**, Hideshima T, Anderson KC, Ghobrial IM. The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia. *Blood* 2006; 108: 2418.
12. Leleu X, Ngo H, Runnels J, Pitsillides C, Spencer J, Moreau AS, **Treon SP**, Hideshima T, Jia X, O' Sullivan G, **Treon SP**, Hideshima T, Lin C, Anderson KC, Ghobrial IM. The PI3K/Akt Pathway Is an Important Regulator of Homing and Adhesion in Waldenstrom's Macroglobulinemia. *Blood* 2006; 108: 2417.
13. Leleu X, O' Sullivan G, Jia X, Moreau AS, Ngo H, Hatjiharrissi E, Yasui H, Hunter ZR, Tai Y, Runnels J, **Treon SP**, Hideshima T, Anderson KC, Ghobrial IM. Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom's Macroglobulinemia. *Blood* 2006; 108: 2517.
14. Moreau AS, Leleu X, Manning R, Coiteux V, Darre S, Hatjiharrissi E, Hunter Z, Jia X, Ngo H, O'Sullivan G, Santos D, **Treon SP**, Facon T, Anderson KC, Ghobrial IM. Serum Free Light Chain in Waldenstrom Macroglobulinemia. *Blood* 2006; 108: 2420.
15. Leleu, X, Jia X, Moreau AS, Hatjiharissi E, Ngo H, O'Sullivan G, Moreno D, Kiziltepe T, Ocio E, Ho A, Facon T, **Treon SP**, Anderson KC, Ghobrial I. Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia. *Blood* 2006; 108: 2488.
16. Moreau AS, Jia X, O'Sullivan G, Leleu X, Podar K, Daley J, Lalo S, Hatjiharissi E, Ngo H, Raab M, D'Halluin JC, Facon T, Hideshima T, **Treon SP**, Anderson KC, Ghobrial I. The Selective Protein Kinase C β Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom's Macroglobulinemia *Blood* 2006; 108: 2496.

17. Leleu X, Ngo H, Jia X, Morea AS, Hatjiharissi E, Carrasco R, O'Sullivan G, Runnells J, Tai YT, **Treon SP**, Hideshima T, Anderson KC, Ghobrial I. Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom's Macroglobulinemia, the Role of the ERK and PKC Pathways. *Blood* 2006; 108: 2416.
18. Morel P, Duhamel A, Gobbi P, Dimopoulos M, Dhodapkar M, McCoy J, Ocio E, Garcia-Sanz R, **Treon SP**, Leblond V, Kyle R, Barlogie B, Merlini G. International Prognostic Scoring System (IPSS) for Waldenström's Macroglobulinemia (WM). *Blood* 2006; 108: 127.
19. Leleu X, Xu L, Hunter Z, Jia X, Moreau AS, Ho A, Hatjiharissi E, Ngo H, Santos D, O'Connor K, Manning R, Soumerai J, Patterson C, Ghobrial I, **Treon SP**. Endoplasmic Reticulum Stress Is a Target for Therapy in Waldenstrom's Macroglobulinemia (WM). *Blood* 2006; 108: 4641.
20. Leleu X, Xu L, Hunter ZR, Morea AS, Jia X, O'Sullivan G, Bakthavachalam V, Ho A, Hatjiharissi E, Ngo H, Dantos D, O'Connor K, Manning R, Soumerai J, Patterson C, Ghobrial I, **Treon SP**. Abnormal Expression of TRAF Adapter Proteins in Waldenstrom's Macroglobulinemia. *Blood* 2006; 108: 4640.
21. Hunter Z, Leleu X, Hatjiharissi E, Santos D, Xu L, Ho A, Bakthavachalam V, Moreau AS, O'Connor K, Soumerai J, Patterson C, Ghobrial I, Hamilton S, Verselis S, Fox E, **Treon SP**. IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom's Macroglobulinemia (WM). *Blood* 2006; 108: 228.
22. Ngo H, Leleu X, Moreau AS, Hatjiharissi E, Jia X, O' Sullivan G, Runnells J, Villarreal R, Hunter Z, **Treon SP**, Hideshima T, Anderson K, Ghobrial I. Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia. *Blood* 2006; 108: 4653.
23. Soumerai JD, Branagan AR, Patterson CJ, Hunter ZR, **Treon SP**. Long term responses to thalidomide and rituximab in Waldenstrom's Macroglobulinemia. *Proc Am Soc Clin Oncol* 2007; 25: 445s.
24. Leleu XP, Manning R, Soumerai JD, Hunter ZR, Moreau A, Hatjiharissi E, Roccaro A, Adamia S, Patterson CJ, Ghobrial IM, **Treon SP**. Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's Macroglobulinemia patients treated with nucleoside analogues. *Proc Am Soc Clin Oncol* 2007; 25: 445s.

25. Hunter ZR, O'Connor K, Soumerai J, Branagan A, Leleu X, Hatjiharissi E, **Treon SP**. IgG and IgA hypogammaglobulinemia is pervasive in Waldenstrom's Macroglobulinemia regardless of response or type of therapeutic intervention. *Proc Am Soc Clin Oncol* 2007; 25: 451s.
26. Ghobrial IM, Leduc R, Nelson M, Leleu X, Jacobsen E, LaCasce A, DeAngelo D, Fisher D, Brown JR, Schlossman R, Warren D, Soumerai J, O'Connor K, Munshi N, Richardson P, Anderson KC, Witzig TE, **Treon SP**. Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. *Blood* 2007; 110: 195b.
27. Ghobrial IM, Padmanabhan S, Badros A, Nelson M, Leduc R, Leleu X, Warren D, Soumerai J, Birner A, Schlossman R, Munshi N, Richardson P, **Treon SP**, Anderson KC. Phase II Trial of combination Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom's Macroglobulinemia. *Blood* 2007; 110: 195b.
28. Ghobrial IM, Leleu X, Rubin N, Nelson M, Leduc R, Warren D, Allen J, Lovecchio S, Soumerai J, Sportelli P, Birch R, Henderson C, **Treon SP**, Richardson P, Anderson KC. *Blood* 2007; 110: 195b.
29. Soumerai JD, O'Connor KE, Ioakimidis LM, Patterson CJ, Ciccarelli BT, Leduc R, Hunter ZR, Nelson M, Roccaro AM, Leleu X, Hatjiharissi E, Adamia S, Xu L, Ghobrial IM, **Treon SP**. Imatinib Mesylate (Gleevec®) Produces Responses in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia. *Blood* 2007; 110: 759a.
30. Adamia S, Reichert A, Ghosh A, Hodges J, Pilarski P, **Treon SP**, Mant MJ, Reiman T, Belch AR, Pilarski LM. Germline and Somatic Mutations in the Hyaluronan Synthase-1 (HAS1) Gene May Contribute to Oncogenesis in Multiple Myeloma (MM) and Waldenstrom's Macroglobulinemia (WM). *Blood* 2007; 110: 733a.
31. Leleu X, Xu L, Hunter ZR, Adamia S, Hatjiharissi E, Moreau AS, Roccaro AS, Sacco A, Ciccarelli B, Manning RJ, Patterson CJ, Ghobrial IM, **Treon SP**. Biological Sequelae of TRAF2 Downregulation in Waldenstrom Macroglobulinemia Cells. *Blood* 2007; 110: 1032a.
32. Leleu X, Hatjiharissi E, Roccaro AM, Moreau AS, Leduc R, Nelson M, Farag M, **Treon SP**, Ghobrial IM. Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM). *Blood* 2007; 110: 445a.

33. Roccaro A, Leleu X, Sacco A, Jia X, Moreau AS, Ngo H, Azab A, Azab F, Hatjiharissi E, **Treon SP**, Hideshima T, Palladino M, Anderson K, Chauhan D, Ghobrial IM. The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM). *Blood* 2007; 110: 454a.
34. Leleu X, Jerome E, Jia X, Moreau AS, Roccaro AM, Farag M, Sacco A, Hatjiharissi E, Ngo H, Runnels J, Azab A, Azab F, Hunter Z, Sportelli P, **Treon SP**, Hideshima T, Anderson KC, Ghobrial IM. Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM). *Blood* 2007; 110: 741a.
35. Roccaro A, Leleu X, Moreau AS, Sacco A, Xu L, Hatjiharissi E, Ciccarelli B, Patterson CJ, Adamia S, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, **Treon SP**. Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom's Macroglobulinemia. *Blood* 2007; 110: 415a.
36. Hatjiharissi E, Mitsiades CS, Ciccarelli B, Lian X, Cao Y, Adamia S, Leleu X, Roccaro A, Ioakimidis L, Hunter ZR, Patterson CJ, Ghobrial IM, **Treon SP**. Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom's Macroglobulinemia by Gene Expression Profiling. *Blood* 2007; 110: 933a.
37. Adamia S, Xu L, Sacco A, **Treon SP**. Identification Genetic Variations (GVs) Causing Splicing of TNF Family Members and Adaptor Proteins That Modulate NFkB Pathways in Waldenstrom's Maroglobulinemia (WM). *Blood* 2007; 110:742a.
38. Elswa SF, Novak AJ, Ziesmer SC, Witzig TE, **Treon SP**, Ansell SM. Role of CCL5 and Interleukin-6 in the Biology of Waldenstrom Macroglobulinemia. *Blood* 2007; 110: 212a.
39. Hatjiharissi, E, Mitsiades CS, Ciccarelli B, Xu L, Cao Y, Adamia S, Leleu X, Roccaro A, Ioakimidis L, Hunter ZR, Patterson CJ, Ghobrial I, **Treon SP**. Comprehensive Molecular Characterization of malignant and microenvironmental cells in Waldenstrom's Macroglobulinemia by Gene Expression Profiling. *Blood* 2007; 110: 933a.
40. Ghobrial IM, Leleu X, Rubin N, Nelson M, Leduc R, Warren D, Allen J, Lovecchio S, Soumerai JD, Sportelli P, Birch R, Henderson C, **Treon SP**, Richardson P, Anderson KC. Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. *Blood* 2007; 110: 194b.
41. Ghobrial IM, Padmanabhan S, Badros A, Nelson M, Leduc R, Leleu X, Warren D, Soumerai J, Birner A, Schlossman R, Munshi N, Richardson P, **Treon SP**, Anderson KC. Phase II

- Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. *Blood* 2007; 110: 195b.
42. Ghobrial IM, Leduc R, Nelson M, Leleu X, Jacobsen E, LaCasce A, DeAngelo D, Fisher DM, Jennifer R, Schlossman R, Warren D, Soumerai J, O'Connor K, Munshi N, Richardson P, Anderson KC, Witzig TE, **Treon SP**. Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. *Blood* 2007; 110: 195b.
 43. Elswa SF, Novak AJ, Ziesmer SC, Witzig TE, **Treon SP**, Ansell SM. Role of CCL5 and Interleukin-6 in the Biology of Waldenstrom Macroglobulinemia. *Blood* 2007; 110: 212a.
 44. Leleu X, Xu L, Hunter ZR, Adamia S, Hatjiharissi E, Moreau A, Roccaro A, Sacco A, Ciccarelli B, Manning RJ, Patterson CJ, Ghobrial IM, **Treon SP**. Biological Sequelae of TRAF2 Downregulation in Waldenstrom Macroglobulinemia Cells. *Blood* 2007; 110: 1032a.
 45. Adamia S, Reichert A, Ghosh A, Hodges J, Pilarski P, **Treon SP**, Mant MJ, Reiman T, Belch AR, Pilarski LM. Germline and Somatic Mutations in the Hyaluronan Synthase 1 (HAS1) Gene May Contribute to Oncogenesis in Multiple Myeloma (MM) and Waldenstrom's Macroglobulinemia (WM). *Blood* 2007; 110: 733a.
 46. Leleu X, Jerome E, Jia X, Moreau A, Roccaro Am, Farag M, Sacco A, Hatjiharissi E, Ngo HT, Runnels J, Azab A, Azab F, Hunter Z, Sportelli P, **Treon SP**, Hideshima T, Anderson KC, Ghobrial IM. Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM). *Blood* 2007; 110: 741a.
 47. Adamia S, Xu L, Sacco A, **Treon SP**. Identification Genetic Variations (GVs) Causing Splicing of TNF Family Members and Adaptor Proteins That Modulate NFkB Pathways in Waldenstrom's Maroglobulinemia (WM). *Blood* 2007; 110: 742a.
 48. Pilarski LM, Adamia S, Reichert A, Ghosh A, Mant MJ, Reiman T, **Treon SP**, Belch AR. Inherited and Acquired Mutations in Waldenstrom's Macroglobulinemia (WM): WM and MM Have Close Genetic Relationships not Shared with B-CLL. *Haematologica* 2007; 92:80.
 49. **Treon SP**, Soumerai JD, Hunter ZR, Patterson CJ, Branagan AR, O'Connor K, Ghobrial IM. Novel Agents in the Treatment of Waldenstrom's Macroglobulinemias: Update of the WMCTG Clinical Trials. *Haematologica* 2007; 92: 91.

50. Hatjiharissi , Zhan F, Adamia S, Ciccarelli BT, Cao Y, Xu L, Hu H, Hunter ZR, Patterson CJ, Ghobrial IM, Barlogie B, Shaughnessy JD, **Treon SP**. Gene Expression Profiling of Waldenstrom's Macroglobulinemia Reveals Genes that may be Related to Disease Pathogenesis. *Haematologica* 2007; 92: 93.
51. Hatjiharissi E, Adamia S, Cao Y, Ciccarelli BT, Xu L, **Treon SP**. Novel Splice Variant Transcript of Siva in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 93.
52. Adamia S , Xu L, Hatjiharissi E, Ciccarelli BT, Cao Y, Sacco A, Hunter ZR, Patterson CJ, **Treon SP**. Aberrant Post-Transcriptional Regulation of the Family Members and their Adaptor Molecules Essential to B-Cell Growth and Survival in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 94.
53. Ciccarelli BT, Hatjiharissi E, Ho AW, Branagan AR, Hunter ZR, Adamia S, Leleu X, Xu L, O'Connor KE, Manning RJ, Santos DD, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Grewal IS, **Treon SP**. The Functional Role of CD27-CD70 Interactions in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 94.
54. Soumerai JD, Branagan A, Hunter Z, Patterson C, Hatjiharissi E, **Treon SP**. Use of the Immunomodulators Thalidomide and Lenalidomide to Augment Rituximab Clinical Activity in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 95.
55. Leleu X, Manning R, Soumerai J, Hunter ZR, Moreau AS, E. Hatjiharissi,1 A. Roccaro, Sacco A, Adamia S, Patterson CJ, Ghobrial IM, **Treon SP**. Increased Incidence of Disease Transformation and Development of MDS/AML in Waldenstrom's Macroglobulinemia (WM) Patients Treated with Nucleoside Analogues. *Haematologica* 2007; 92: 95.
56. Hunter ZR, Leleu X, Adamia S, Hatjiharissi E, Xu L, Ciccarelli B, Ioakimidis L, Moreau AS, O'Connor KE, Soumerai J, Patterson C, Hamilton S, Verselis S, Fox EA, **Treon SP**. Genomic Mutations in the APRIL/TACI/TRAF Pathway in Waldenstrom's Macroglobulinemia (WM). *Haematologica* 2007; 92: 220.
57. Ngo H, Leleu X, Runnels J, Moreau AS, Jia X,1 Roccaro A, Sacco A, Hatjiharissi E, **Treon SP**, Hideshima T, Anderson KC, Ghobrial I. CXCR4 and VLA-4 Interaction Promotes Adhesion of Waldenstrom's Macroglobulinemia Cells. *Haematologica* 2007; 92: 222.
58. Roccaro AM, Leleu X, Moreau AS, Patterson CJ, Xu L, Jia X, Ngo H, Sacco A, Cao J, Ciccarelli B, Manning R, Adamia S, Hatjiharissi E, Russo D, Vacca A, Dammacco F, Ghobrial IM, **Treon SP**. Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 224.

59. Moreau AS, Jia X, Leleu X, Patterson CJ, Hunter ZR, Roccaro AM, Sacco A, Soumerai J, O'Connor K, Ciccarelli B, Xu L, Manning R, Ghobrial IM, **Treon SP**. Simvastatin, an HMG-COA Inhibitor Induces *in vitro* Antitumor Activity in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 225.
60. Moreau AS, Jia X, Ngo H, Leleu X, Daley J, Lalo S, O'Sullivan G, Roccaro A, Hatjiharisi E, Raab MS, Podar K, D'Halluin JC, Facon T, **Treon SP**, Hideshima T, Anderson K, Ghobrial I. Protein Kinase Inhibitor, Enzastaurin, Induces *in vitro* and *in vivo* Antitumor Activity in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 225.
61. Leleu X, Jia X, Moreau AS, Ngo H, Runnels J, Hatjiharisi E, Roccaro A, O'Sullivan G, Moreno D, Kiziltepe T, Facon T, **Treon SP**, Hideshima T, Anderson K, Ghobrial I. Perifosin, an Oral Bioactive Novel AKT Inhibitor, Induces *in vitro* and *in vivo* Antitumor Activity in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 225.
62. Leleu X, Jia X, Moreau AS, Ngo H, Runnels J, Roccaro A, Kiziltepe T, Ciccarelli B, Hatjiharissi E, Hunter Z, Adamia S, Sportelli SP, **Treon SP**, Anderson K, Ghobrial I. Haematologica June 2007; v92: 6: s2. The Combination of Perifosine with Bortezomib and Rituximab Provides Synergistic Anti-tumor activity in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 226.
63. Ghobrial IM, Leleu X, **Treon SP**, Nelson MB, Leduc R, Warren D, Soumerai J, Ngo H, Sportelli P, Birch R, Henderson IC, Richardson P, Anderson K. Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom's Macroglobulinemia: Preliminary Results. *Haematologica* 2007; 92: 226.
64. Leleu X, Moreau AS, Manning R, Coiteux V, Darre S, Nelson M, Leduc R, Poulain S, Faucompret L, Hennache B, **Treon SP**, Facon T, Ghobrial IM. Serum Free Light Chain is a Marker of Tumor Burden and of Prognostic Impact in Waldenstrom's Macroglobulinemia. *Haematologica* 2007; 92: 229.
65. Adamia S, Hatjiharissi E, Cao Y, Ioakimidis L, Hunter Z, Manning R, Ciccarelli B, Patterson C, **Treon SP**. Abnormal splice variants of SIVA in Waldenstrom's macroglobulinemia (WM). *Proc. AACR* 2008; 14:2695.
66. Xu L, Hatjiharissi E, Ciccarelli BT, Roccaro AM, Adamia S, Sacco A, Hunter RZ, Manning RJ, Ioakimidis L, Patterson CJ, **Treon SP**. Expression of the deleted in liver cancer-1 gene is regulated by DNA methylation and is a target for therapy in Waldenström's Macroglobulinemia. *Proc Am Soc Clin Oncol* 2008; 26: 718s.

67. Hunter ZR, Ioakimidis L, Soumerai JD, Patterson CJ, Xu L, Leleu X, Ciccarella BT, Sacco A, Adamia S, Hatjiharissi E, **Treon SP**. Increased prevalence of monoclonal gammopathy, abnormal immunoglobulin levels, and recurrent infections in family members of patients with familial Waldenstrom's macroglobulinemia. Proc Am Soc Clin Oncol 2008; 26: 464s.
68. Ghobrial IM, Leleu X, Rubin N, Leduc R, Chuma S, Nelson M, Sportelli P, Richardson PG, **Treon SP**, Anderson KC. Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). Proc Am Soc Clin Oncol 2008; 26: 465s.
69. **Treon SP**, Ioakimidis L, Soumerai JD, Patterson CJ, Hunter ZR, Feiner A, Mattern J, Birner A, Boral A, Ghobrial IM. Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: Results of WMCTG clinical trial 05-180. Proc Am Soc Clin Oncol 2008; 26: 458s.
70. Hatjiharissi E, Ciccarella BT, Ioakimidis L, Borok R, Soumerai JD, Manning RJ, Hunter ZR, Xu L, Patterson CJ, Alvin S, **Treon SP**. Serum Immunoglobulin free light chains as markers of disease burden and response to treatment in patients with Waldenstrom's macroglobulinemia. Proc Am Soc Clin Oncol 2008; 26: 482s.
71. Ciccarella BT, Hatjiharissi E, Soumerai JD, Hunter ZR, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Adamia S, **Treon SP**. Use of soluble CD27 as a marker of disease burden and the effect of rituximab-induced IgM flare and plasmapheresis in patients with Waldenström's macroglobulinemia. Proc Am Soc Clin Oncol 2008; 26: 474s.
72. Ghobrial IM, Matous J, Padmanabhan S, Badros A, Schlossman R, Chuma S, Leduc R, Nelson M, O'Connor K, Sam A, Harris B, Soumerai J, Warren D, Birner A, Munshi N, **Treon SP**, Anderson KC, Richardson P. Phase II Trial of Combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom Macroglobulinemia. Blood 2008; 112: 832.
73. **Treon SP**, Branagan A, Ioakimidis L, Soumerai J, Patterson C, Wasi P, Emmanouilides C, Frankel SR, Lister TA, Morel P, Matous J, Gregory SA, Kimby EK. Long term responses to fludarabine and rituximab in Waldenstrom's Macroglobulinemia. Blood 2008; 112: 3057.
74. **Treon SP**, Hunter Z, Ciccarella B, Zhou Y, Hanzis C, Manning R, Ioakimidis L, Xu L, Patterson C, Morra M. IgA and IgG hypogammaglobulinemia is a constitutive feature in most Waldenstrom's Macroglobulinemia patients and may be related to mutations associated with Common Variable Immunodeficiency Disorder (CVID). Blood 2008; 112: 3749.

75. Adamia S, Amin SB, Li C, Patterson CJ, Avet-Loiseau H, Minvielle S, Moreau P, Anderson KC, Munshi NC, **Treon SP**. High-throughput microRNA profiling in patients with Waldenstrom's Macroglobulinemia. *Blood* 2008; 112: 1704.
76. Adamia S, Avet-Loiseau H, Amin SB, Tai YT, **Treon SP**, Moreau P, Minvielle S, Li C, Anderson KC, Munshi NC. MicroRNA Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy. *Blood* 2008; 112: 96.
77. Ghobrial IM, Leleu X, Rubin N, Xie W, Hong F, Chuma S, Leduc R, Nelson M, O'Connor K, Sam A, Harris B, Warren D, Sportelli P, **Treon SP**, Weller E, Anderson KC, Richardson PG. Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM). *Blood* 2008; 112: 1010.
78. Ghobrial IM, Chuma S, Sam A, Leduc R, Nelson M, O'Connor K, Harris B, Soumerai J, Warren D, Jacobsen E, DeAngelo D, Anderson KC, Richardson PG, Witzig TE, **Treon SP**. Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience. *Blood* 2008; 112: 1011.
79. Ioakimidis L, Patterson C, Soumerai J, Manning R, Sheehy P, **Treon SP**. Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom's Macroglobulinemia. *Blood* 2008; 112: 2011.
80. Ghobrial I, Gertz M, LaPlant B, Camoriano J, Hayman S, Lacy M, Chuma S, Sheehy P, Harris B, Leduc R, Rourke M, Ansell S, DeAngelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson K, Richardson P, **Treon SP**. Phase II Trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom's Macroglobulinemia. *Blood* 2009; 114: 587.
81. Yang G, Gong P, Ioakimidis L, Xu L, Hunter ZH, Sun J, Ciccarelli B, Zhou Y, Liu X, Tseng H, Cao Y, Manning R, Lewicki M, Hanzis C, Sheehy P, Patterson C, **Treon SP**. The IgM flare following Rituximab and IVIG administration in Waldenstrom's macroglobulinemia is related to IL-6 production by Bystander immune cells, possibly through stimulation of the FCγRIIA receptor. *Blood* 2009; 114: 761.

82. Hunter ZH, Hanzis C, Ioakimidis L, Patterson CJ, Ciccarelli B, Lewicki M, Manning R, Tseng H, Xu L, Liu X, Tseng H, Gong P, Sun J, Zhou Y, Yang G, Sheehy P, Fox E, **Treon SP**. Genome wide association studies of Familial Waldenstrom's macroglobulinemia (WM) reveals a loss of GSTM1 is common in families with a history of B-cell disorders but not in those with a history specific for WM. *Blood* 2009; 114: 762.
83. Hunter ZH, Manning R, Hanzis C, Ciccarelli, Ioakimidis L, Patterson CJ, Lewicki M, Tseng H, Gong P, Liu X, Zhou Y, Yang G, Sun J, Xu L, Sheehy P, Massimo M, **Treon SP**. IgA and IgG Hypogammaglobulinemia Does not predict for Recurrent Infection risk and persists despite Therapeutic reponse in patients with Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 1947
84. Ghobrial I, Hong F, Padmanabham S, Badros A, Leduc R, Rourke M, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson K, Richardson P, **Treon SP**, Weller E, Matous J. Phase II Trial of weekly Bortezomib in combination with Rituximab in relapsed or relapsed-refractory Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 2727.
85. Zhou Y, Liu X, Xu L, Hunter ZH, Sun J, Yang G, Gong P, Ciccarelli B, Patterson C, Garrett-Sinha L, **Treon SP**. Involvement of Ets Factor Spi-B, E protein E2-2, and Id2 in Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 2946.
86. Yang G, Hanzis C, Gong P, Verselis S, Fox E, Xu L, Ciccarelli B, Zhou Y, Hunter ZH, Sun J, Liu X, Tseng H, Cao Y, Manning R, Lewicki M, Ioakimidis L, Sheehy P, Patterson C, **Treon SP**. Polymorphisms of Fc γ RIIA, Fc γ RIIB, Fc γ RIIIA, and Therapeutic reponse to Rituximab combination therapy in patients with Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 2949.
87. Hunter ZH, Sun J, Adamia S, Cao Y, Tseng H, Lewicki M, Xu L, Yang G, Zhou Y, Xia L, Gong P, Hanzis C, Ioakimidis L, Ciccarelli B, Manning R, Sheehy P, Patterson C, Andry C **Treon SP**. Micro-RNA expression profiling reveals distinct correlates to disease pathogenesis and identifies novel pathways involved in tumor cell senescence and IL-12A signaling. *Blood* 2009; 114: 2950.
88. Ciccarelli B, Patterson CJ, Hunter ZH, Hanzis C, Ioakimidis L, Manning R, Yang G, Gong P, Xu L, Zhou Y, Sun J, Liu X, Tseng H, Cao Y, Sheehy P, **Treon SP**. Patients with Waldenstrom's macroglobulinemia are often Hypoferremic that is refractory to oral iron repletion and responsive to parental iron infusions, and demonstrate elevated levels of Hcpidin. *Blood* 2009; 114: 2952.

89. Xu L, Ciccarelli B, Hatjiharissi E, Yang G, Zhou Y, Hunter ZH, Sun J, Gong P, Liu X, Tseng H, Ioakimidis L, Manning R, Hanzis C, Cao Y, Lewicki M, Patterson C, **Treon SP**. Aberrant DNA methylation and transcriptional silencing of DLC-1 in Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 2954
90. Ghobrial I, Padmanabham S, Badros A, Leduc R, Rourke M, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson K, Richardson P, **Treon SP**. Phase II Trial of weekly Bortezomib in combination with Rituximab in untreated patients with Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 3752.
91. Ghobrial I, Harousseau J, **Treon SP**, Harris B, Lin C, Yuan Z, Benhadji K, Wooldridge J, Leblond V. Enzastaurin in previously treated Waldenstrom's macroglobulinemia: an open-label, multicenter, Phase II Study. *Blood* 2009; 114: 3867.
92. Hunter ZH, Hatjiharissi E, Sun J, Cao Y, Tseng H, Lewicki M, Xu L, Yang G, Zhou Y, Liu X, Gong P, Hanzis C, Ioakimidis L, Patterson C, Sheehy P, Barlogie B, Shaughnessy J, **Treon SP**. Gene Expression profiling distinguishes Waldenstrom's macroglobulinemia patients presenting with Familial disease. Advanced IPSS prognostic Score, and previous treatment with Rituximab. *Blood* 2009; 114: 3930.
93. **Grass S**, Preuss K, Wikowicz A, Terpos E, Ziepert M, Ahlgrimm M, Fadle N, Regitz E, Murawski N, Dimopoulos M, **Treon SP**, Hunter ZH, Pfreundschuh M. Hyperphosphorylated Paratarg-7 Is a Frequent Antigenic Target of IgM Paraproteins, Is Dominantly Inherited and Represents a Highly Significant Risk Factor for Monoclonal Gammopathy of Undetermined Significance of the IgM Type (IgM-MGUS) and Waldenstrom's Macroglobulinemia (WM), Allowing for the Identification of Family Members at Risk in Cases of Familial IgM-MGUS and WM. *Blood* 2009; 114:3935.
94. Xu L, Patterson CJ, Sun J, Yang G, Zhou Y, Hunter ZH, Hatjiharissi E, Ciccarelli B, Gong P, Liu X, Tseng H, Ioakimidis L, Manning R, Hanzis C, Cao Y, Lewicki M, **Treon SP**. Involvement of Fatty acid synthase in Azacytidine-Induced cytotoxicity in Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 3731.
95. Yang G, Gong P, Xu L, Hunter ZH, Sun J, Ciccarelli B, Zhou Y, Liu X, Tseng H, Cao Y, Manning R, Lewicki M, Hanzis C, Ioakimidis L, Sheehy P, Patterson C, **Treon SP**. The Inhibitory receptor FcγRIIB is overexpressed, and its ligation by anti-FcγRIIB antibodies suppresses IgM production and induces apoptosis in Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 3736.

96. Sun J, Tseng H, Xu L, Hunter ZH, Ciccarelli BT, Fulciniti M, Yang G, Gong P, Zhou Y, Liu X, Munshi N, Patterson C, **Treon SP**. Vorinostat induced cellular stress disrupts the balance between p38 MAPK and Erk pathways leading to apoptosis in WM cells. *Blood* 2009; 114: 3740.
97. **Treon SP**, Hanzis C, Manning R, Ioakimidis L, Patterson CJ, Hunter ZH, Turnbull B, Sheehy P. Maintenance Rituximab is associated with improved progression free and overall survival in Waldenstrom's macroglobulinemia. *Blood* 2009; 114: 3750.
98. Zhou Y, Liu X, Gong P, Xu L, Ciccarelli B, Yang G, Patterson CJ, **Treon SP**. Metalloproteinase inhibitors inhibit the release of soluble CD27 by Waldenstrom's macroglobulinemia cells. *Blood* 2009; 114: 3942.
99. Sun J, Xu L, Tseng H, Ciccarelli B, Fulciniti M, Hunter ZH, Maghsoudi K, Hatjiharissi E, Zhou Y, Yang G, Zhu B, Liu X, Gong P, Ioakimidis L, Sheehy P, Manning R, Hanzis C, Lewicki M, Patterson CJ, Chauhan D, Rodig S, Munshi N, Anderson K, O'Connor O, **Treon SP**. Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia. *Blood* 2009; 114: 4785
100. Ioakimidis L, Patterson CJ, Hunter ZH, Soumerai J, Manning R, Warren D, Ghobrial I, Sheehy P, **Treon SP**. Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia. *Blood* 2009; 114: 4789.
101. **Treon SP**, Ioakimidis L, Hanzis C, Manning R, Patterson CJ, Hunter ZH, Sheehy P, Turnbull B. Progression Free Survival Is Predicated by Categorical Response, and Supports the Attainment of VGPR/CR as An Objective for Long Term Disease Control in Waldenstrom's Macroglobulinemia. *Blood* 2009; 114: 4993.
102. Ciccarelli B, Freiberg A, Hatjiharissi E, Dorrwachter J, Rooney P, Xu L, Rezuke W, O'Brien A, Ciccarelli C, Rubash H, **Treon SP**. A novel methodology for the utilization of intramedullary aspirates from total joint arthroplasty [TJA]: a low-cost, alternative source of normal hematopoietic cells [NHC] *Proc. AACR* 2010: 3991.